

Epigenetic mechanisms in maternal-fetal crosstalk: inter- and trans-generational inheritance

Veronica Tisato^{a,b,c}, Elisabetta D'Aversa^a, Francesca Salvatori^a, Marco Sbracia^d, Giuseppina Peluso^e, Fabio Scarpellini^d and Donato Gemmati^{a,b,f}

^aDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy; ^bUniversity Strategic Centre for Studies on Gender Medicine, University of Ferrara, Ferrara, Italy; ^cLTTA Centre, University of Ferrara, Ferrara, Italy; ^dCERM Hungaria, Centre for Reproductive Medicine, Rome, Italy; ^eSperm Bank, Department of Maternal Infant, A.O. of Cosenza, Cosenza, Italy; ^fCentre Haemostasis Thrombosis, University of Ferrara, Ferrara, Italy

ABSTRACT

Epigenetics as a composite language capable of translating signals from the environment into heritable DNA modifications is revolutionizing the approach to biology and medicine. In the field of human reproductive physiology, many epigenetic marks have been decoded in the different stages of development, from gametogenesis to embryo development, pregnancy and its maintenance. These epigenetics marks are mainly ascribable to DNA methylation/demethylation processes, histone modifications, and non-coding RNAs mediated signals. Epigenetic modifiers such as DNA methyltransferases (DNMTs) and Ten-eleven translocation (TET) enzymes are involved in gene expression regulation by modifying the DNA methylation landscape, the first and best characterized epigenetic mark. In the context of human reproduction, epigenetics signals depict the mother-fetus crosstalk in which the maternal milieu dialogs with the growing embryo to establish an appropriate placental-fetal interface for a successful pregnancy. We here outline key features of the epigenetic crosstalk during the early embryo development and pregnancy establishment. The potential of inter- and trans-generational inheritance of specific epigenetic traits in response to environmental hints is also discussed. Finally, we move forward into future translational developments of epigenetics by discussing the potential use of epigenetic-based treatments (epidrugs) as upcoming therapeutic approaches in advanced personalized reproductive medicine.

PLAIN LANGUAGE SUMMARY

The genetic information we need to develop, grow-up, and live is carried by the DNA, a molecule present in all cells of living beings that contains, as a sort of instruction book, the letters that codify for the different proteins we need. Each gene can be imagined as a specific paragraph of the immense DNA book providing the specific information for a specific protein. Changes in letters or in the sequence of letters determine modifications of the instructions carried by the DNA. In response to environmental factors (such as physical or chemical agents) and personal habits (such as diet, physical activity), DNA may undergo a different type of modifications called “epigenetic modifications.” Using the same metaphor of the book, we can think of epigenetic modifications to the DNA sequence as spaces, punctuation, and accents on words: they do not change the sequence of letters that make up the word, but rather the format of the text. Epigenetic characteristics change throughout life and can be passed from a dividing cell to its daughter cells, and from parents to offspring influencing development, health, and disease risk. The study of epigenetic modifications will allow the identification of appropriate behaviors and the development of pharmacological treatments.

ARTICLE HISTORY

Received 23 June 2025
Accepted 25 September 2025

KEYWORDS

Epigenetic mechanisms; inter- and trans-generational inheritance; methylation; histone modifications; miRNAs; epidrugs; human reproductive medicine; curable epigenome; First 1000 days of life



Article highlights

- Epigenetic mechanisms link environmental variations and gene regulation
- Epigenetic dynamics are crucial during development and after birth in determining health and disease
- The maternal environment and the developing embryo communicate using an epigenetic-based language
- The transmission of epigenetic marks may result into inter- and trans-generational inheritance
- Epigenetic-based treatments (Epidrugs) may represent a breakthrough in human reproduction

1. Introduction

Epigenetics plays a crucial role during embryo development in driving cell lineage commitment, in establishing cellular identity and tissue specification, with after birth effects in determining individual health. The term Epigenetics was proposed for the first time by Conrad Hal Waddington in the 1940s as complex landscape of interactions between the environment and the genome that lead to the production of phenotype [1,2]. Only more recently, in 2008, a new definition has been proposed: “a stably heritable phenotype resulting from changes in a chromosome without alterations in the DNA sequence.” Since then, the relevance of epigenetics has massively increased, resulting into a field that is now changing our comprehension of gene regulation, heredity, and modern biomedicine [3,4]. As a paradigm of the “revolution” that epigenetics is driving, epigenetics relies on genome modifications not resulting in altered DNA sequence, able to give rise to alternative gene activities and functions that may be transmissible and durable, outlining a complex biological context that is developing over time [5].

Normally, the epigenome undergoes continuous remodeling in which epigenetic marks are dynamically established and erased in response to exogenous or endogenous stimuli overall shaping genome architecture [6]. The epigenetic marks are the result of several molecular paths, among these an important and well-studied mechanism is the cytosine methylation, which plays important roles such as transcriptional regulation, through silencing and tuning gene promoters, genomic imprinting, and individual stress response and coping [7,8]. Other epigenetic modifications that allow the regulation of gene expression and reprogramming, also during gametogenesis and embryo development, include histone post-translational modifications, which makes DNA accessible or not to transcriptional factors [9–11], and the regulation of gene activity by non-coding RNAs (ncRNAs) [6,12].

DNA methylation represents a key epigenetic control mechanism in mammalian development, with a dynamic that shapes two fundamental phases: primordial germ cell (PGCs) specification and zygote progression upon fertilization. PGCs are the embryonic precursors of mature gametes that originate in the epiblast in response to bone morphogenic protein signals [13–15]. The molecular and epigenetic changes occurring in the developing embryo are driven by extra-embryonic tissues and microenvironmental triggers, able to induce a distinctive genetic and epigenetic regulatory landscape for PGCs specification [15]. In humans, PGCs proliferate and mature during their migration to the developing

gonads approximately at 4 weeks of development, resulting into precursors able to differentiate into functional mature gametes at puberty. Notably, to erase parental epigenetic memory, a specific PGCs epigenetic reprogramming starts immediately following specification and continues up to PGCs arrival in the developing gonads [16].

We are referring to a complex dynamic set of events that includes the extensive erasure of global DNA methylation marks (leading to less than 5% residual DNA methylation), in concomitance with independent DNA methylations and histone modifications to preserve crucial transcriptional control. This extensive DNA demethylation leads to the comprehensive removal of most parental somatic signatures and those epigenetic marks in PGCs necessary for totipotency reprogramming and subsequent embryonic development [17,18]. After erasure, in later stages of development (before birth in male and after birth in female), de novo methylation will ensure during the individual gametogenesis a sex-specific reestablishment of epigenetic signatures, including the methylation marks at imprinted loci [19] (Figure 1). Moreover, histone post-translational modifications represent additional epigenetic-based key mechanisms of gene regulation. Histones molecular changes, including acetylation, methylation, phosphorylation, and ubiquitination, overall result in chromatin structural organization allowing the switch between hetero- and euchromatin architecture [20], also influenced by external environmental triggers. Among the identified histone modifications we can mention histone H3 trimethylation at lysine 4 and 27, and histone H3 acetylation at lysine 9 (see review [21]), contributing to functional states such as open or closed chromatin, active or repressed genes, poised or operative enhancers [22]. Of note, the majority of gene body CpG islands results methylated ($\geq 55\%$ methylation), and this state is specifically associated with enrichment of trimethylated histone H3 lysine 36 (H3K36me3), and absence of trimethylated histone H3 lysine 4 (H3K4me3) and trimethylated histone H3 lysine 27 (H3K27me3), suggesting a close link between gene body methylation and histone marks [23,24].

The ncRNAs system is a main epigenetic regulatory complex of different ncRNA clusters classified into long ncRNAs (lncRNAs, longer than 200 nucleotides) and short ncRNAs (sncRNAs, less than 200 nucleotides) including miRNAs, siRNAs, piRNAs, tsRNAs (tRNA derived sncRNAs), and rsRNAs (rRNA derived sncRNAs). A growing body of evidence highlights the role of ncRNAs in gene expression control [12], in the epigenetics of embryo development and in maternal-fetal crosstalk, including the establishment and maintenance of imprinted genes expression [25]. The role of ncRNAs in the regulation of PGCs epigenetic landscape has been mainly investigated in animal models that allowed the characterization of selected miRNAs (e.g., let-7 miRNA family, miR-17/92, miR-181, miR-290 cluster), piRNAs, and endo-siRNAs, while in humans (excluding some piRNAs) this is a field still in its infancy [26].

During pregnancy, fetal membranes and decidua undergo epigenetic modifications in which chromatin changes are involved in tissue gene regulation [22]. Therefore, embryo development and pregnancy progression underlie the regulatory effect of specific pathways that are tightly regulated by

environmental-epigenetic signals. In this line, the mutual communication between the developing inner cell mass of Embryonic Stem Cells (ESC), the trophectoderm and the endometrial epithelium is mediated by a network of epigenetic molecular factors able to trigger the different phases of the reproductive process. In terms of delivery systems involved in maternal-fetus communication, Extracellular Vesicles (EVs), secreted by both embryonic and maternal cells, have recently attracted attention as epigenomic modifiers [27], with a role in pregnancy and a potential therapeutic target for infertility treatments.

The influence of maternal environment on offspring development and phenotype is overall referred as the “maternal effect,” in which the intrauterine milieu may result into a non-genetic transfer of marks and signatures to the developing embryo and across generations.

The present review is focused on the role of epigenetic mother-fetus crosstalk during early embryonic development and pregnancy establishment, highlighting the key mediators and modifications in controlling the specific developmental phases. Finally, we discuss on how environmental hints may

result into epigenetic inter- or trans-generational inheritance, and how epigenetic treatments (epidrugs) may be considered upcoming therapeutic approaches in the field of human reproductive medicine.

1.1. Zygote-genome-activation (ZGA) and Blastocyst Dormancy

Upon fertilization, the primary event of early embryonic development entails the transition from maternally derived gene products (i.e., maternal transcripts) to zygote-genome-activation (ZGA). These are two extremely coordinated cytoplasmic and nuclear reprogramming processes overall referred to as the maternal-to-zygotic transition (MZT) [28]. In humans, oocyte-derived maternal mRNA decay occurs during MZT reaching the major effect at the 8-cells stage, and it has been demonstrated that subgroups of maternal transcripts are sequentially removed by maternal (M)- and zygotic (Z)-decay pathways before and after ZGA [29]. Timing of clearance may depend on the specific mRNA and there might be a time-




Figure 1. Methyome and miRnome dynamics during human development. (A) PGCs epigenetic reprogramming process lasts up to PGCs arrival in the developing gonads. The process comprises a global erasure of DNA and RNA methylation (red and green line, respectively). This extensive demethylation process leads to the removal of epigenetic marks in PGCs necessary for reprogramming. A remethylation occurs at the time of sperm and oocyte maturation resulting fully differentiated. After fertilization, a new wave of demethylation takes place. Specifically, DNA methylation is sex-differentiated (red dotted lines). DNA re- and de-methylation of the paternal hemigenome is rapid compared to the maternal hemigenome. Concomitant with blastocyst implantation and cell-lineage determination, an epigenetic re-patterning occurs with *de novo* DNA and RNA methylation to establish cell lineage-specific gene expression. (B) miRnome pattern changes immediately after the first embryo division, where 60% of miRNAs are downregulated in the 2-cell stage. At the time of implantation, the miRnome pattern is upregulated again to ensure pregnancy establishment and maintenance. Created in BioRender. Tisato, V. (2025) <https://biorender.com/iip4nn0>.

window in which maternal and zygotic transcripts synergize in driving embryo development.

At the time of fertilization, sperm and oocyte are fully differentiated cells characterized by specific and distinctive epigenetic marks and signatures. DNA methylation is consistently distributed in sperm genome reaching approximately 90% levels with the exception of definite CpG islands maintained hypomethylated (e.g., those localized to developmental loci such as HOX genes [30,31]), while mature oocytes show a lower global DNA methylation of about 50% [32,33]. In this context, to allow the development of the zygote into embryo, the terminally differentiated parental genomes undergo complete reprogramming to achieve a totipotent state. One of the main epigenetic modifications occurring is an extensive demethylation process to clean up parental epigenetic marks, except for imprinting control regions (ICR) and specific repetitive sequences that keep their methylation status. Differently from what observed in mouse developmental studies, the major genome-wide demethylation wave in humans is completed at the 2-cells stage [34,35]. Actually, the paternal genome is rapidly and actively demethylated by TET enzymes, while the maternal genome undergoes slower passive demethylation resulting from a dilution-effect during cell division in the absence of DNA methylation maintenance by DNMTs that may be unavailable or nonfunctional at this stage [36]. After fertilization the zygote genome is transcriptionally quiescent with a gradual and controlled transcriptional activation characterized by minor and major wave of transcription [37]. In humans, ZGA occurs by the eight-cells stage, though it has been reported that it already starts at the one-cell stage [38], first from paternal genome [39].

In the subsequent developmental stages, an epigenetic re-patterning occurs with *de novo* DNA, RNA methylation and chromatin remodeling to establish cell lineage-specific gene expression [40,41]. The targeted reestablishment of DNA methylation patterns is primarily mediated by DNMT3A and DNMT3B, which selectively methylate CpG sites to activate gene regulatory networks governing the specification and maintenance of distinct embryonic lineages, including epiblast, primitive endoderm, and trophoblast [42,43].

Maternally inherited epigenetic factors sustain the cleavage divisions of zygote over the first 72 hours post-fertilization before a major wave of embryonic genome activation occurs at the 4-cells stage [37]. After genome activation, human embryos undergo compaction to form first the morula and then the early and late blastocyst with a defined inner cell mass, ready for implantation [44]. Similar to chromatin remodeling, histone modifications are also highly dynamic during all stages of embryo development. From 2–4-cells stages, a gain in H3K4me3 levels and loss in H3K27me3 and H3K9me3 is observed [11,45,46]. In this context, sncRNAs are deeply involved in the transition from maternally provided factors into embryo genome activation. This process also accounts for a switch from mainly maternally derived oocyte-piRNAs to embryonic miRNAs expression in cleavage stage embryos coupled with an extensive process of miRNA modification (e.g., 3' mono- and oligoadenylation) in the zygote [26,47]. Moreover, although less explored than in animal

models, sncRNAs seem to contribute to cellular heterogeneity and to the establishment of embryonic lineages by regulating the pluripotency-network axis, as emerged from cell reprogramming models [48,49].

At the preimplantation stage, there may be an interruption of the ongoing developmental processes and undertakes the embryonic diapause, a period of suspension in which blastocyst implantation and development are delayed [50,51]. We are referring to a reversible phase of embryo development concerning over 130 species of mammals (from bears to mice and marsupials), in which the unplanted blastocyst can survive in the uterus in a dormant state [50,51]. Signals and molecular mechanisms involved in diapause establishing and maintenance have been deeply investigated in animal models, also with the aim to identify the embryo-maternal interactions aimed at having a healthy pregnancy [52,53]. Several factors and life-conditions may induce obligate or facultative blastocyst dormancy such as food availability (also depending on seasonal variations), changes in temperature, and day-light length that act in a species-specific manner. The dormant embryos show common peculiar features including low cell proliferation, low metabolic activity, and transcriptional repression, but they still retain the capability of resuming development when exposed to the appropriate signals/conditions [53]. Studies have revealed that maternal signals exert primary regulatory effects on diapause onset and exit and on their timing/duration [51]. In this line, it has been recently demonstrated that soluble factors of maternal origin may intervene in this process as oxytocin, that is able to coordinate the dynamic embryonic development with uterine progression through pregnancy [54].

The control of the embryo fate and diapause entry/exit have been correlated with several factors and mechanisms, including epigenetic processes and key molecular pathways. Multiple epigenetic modifications characterize embryonic development with key signatures that identify the different developmental stages. Regarding diapause, chromatin remodeling in dormant blastocysts results in a comprehensive reduction of activating epigenetic marks including histone-related modifications as H3K36me3, H3K4me3, and H4K5/8/16/12 acetylation, and in an overall increase in repressive histone modifications such as H3K27me3 [55,56]. These epigenetic marks change when dormant blastocysts exit dormancy and become activated with high correlation to gene expression [56,57]. In a recent work, it has been reported that N6-methyladenosine (m6A) RNA methylation by *Mettl3* is involved in this process by promoting global mRNA destabilization and transcription suppression by acting on the oncogene *N-Myc*, resulting in a key anti-diapause factor [58]. miRNAs are also differentially expressed in dormant or activated blastocysts. One of the most studied is the Lethal-7 (let-7) miRNA family, resulted upregulated in mouse dormant embryo compared to the reactivated ones [59]. Of note, Let-7 belongs to the cargo of the maternal extracellular vesicles (endometrial epithelial cells) and induces diapause by suppressing *c-myc/mTORC1*, and *mTORC2* signaling pathways [56]. Moreover, it inhibits the expression of the ornithine decarboxylase1 enzyme involved into polyamines biosynthesis and reactivation of dormant embryos, resulting into one of the main

factors of embryonic diapause [60]. Other miRNAs play a role in embryo dormancy [56], among these miRNA-199 and miRNA-181, that target the degradation of *EGR1* gene (highly expressed in diapause) and the glutamine transporters *Slc38a1/Slc38a2*, that are downregulated in diapause [61,62].

Embryo development during the preimplantation phase is very sensitive and crucially depends on the exposure to specific signals, and the role of different signaling pathways for successful embryonic progression has been recently reviewed [63]. In the context of diapause, mTOR plays a crucial role, and its inhibition induces reversible pause of blastocyst development preserving the pluripotent state [64].

In conclusion, animal studies revealed that a productive diapause induction, maintenance, and exit with reactivation and establishment of normal pregnancy needs a viable embryo, a receptive uterus and an efficient molecular interaction between the two. Whether these mechanisms may be conserved and maintained in humans is still a matter of discussion. Hypotheses have been advanced [65], and possible isolated cases of delayed implantation after in-vitro fertilization (IVF) have been reported [66], then, the mechanisms underlying the embryo-maternal crosstalk during diapause have been suggested as useful tools for a better understanding of human ART/IVF approaches. In these techniques, mother and embryo are separated until transfer and this requires a perfect timing and biological coordination that may take advantage from diapause insights [67]. In this line, starting from the evidence that mTOR pathway is a key regulator of diapause in mice, in a recent work Iyer and colleagues have reported new understanding on potential diapause-like dormant state in human [68]. In particular, by using a human stem cell-based model of the blastocyst (blastoids) and blastocyst-stage human pluripotent stem cells, they showed that the inhibition of mTOR leads to the maintenance of cellular identity and drives the onset of a reversible state of restricted proliferation and developmental progression [68]. This suggests that mTOR maintains its role in growth and development regulation of human blastocyst-stage-like cells. These findings are relevant for the comprehensive understanding of human embryogenesis and as potential translational tool in ART procedures. In particular, the modulation of mTOR pathway may be exploited to control and extend the time window at the pre-implantation stage and optimize the embryo-maternal molecular synchronization [68].

1.2. Embryo-endometrial crosstalk during the implantation process: insights on epigenetic signals

Endometrial receptivity plays a pivotal role in successful embryo implantation. Nevertheless, for a successful pregnancy there is the need for a competent blastocyst and appropriate microenvironment conditions, since a poor fetal-maternal interface may result in pregnancy complications or reproductive failure. At the time of blastocyst implantation during the apposition phase the reproductive microenvironment is shaped by both blastocyst-derived and maternal-derived factors. ESCs of the blastocyst secrete extracellular vesicles and nano-sized membrane enclosed vesicles (exosomes) carrying proteins and nucleic

acids. Among these, cell surface receptors, signaling proteins, extracellular matrix proteins, mRNAs, miRNAs, and DNA are able to communicate with the trophoblast and activate signaling events including the trophoblast ability to migrate, promoting in turn blastocyst implantation [69]. These molecular mediators coordinate both endometrial receptivity and embryonic epigenetics, and prime epithelial endometrial cell receptivity increasing the adhesive capability of the endometrium [69,70]. Epithelial and stromal cells of endometrium produce and secrete several cytokines and growth factors, such as VEGF, G-CSF, LIF, and Preimplantation Factor (PIF) which regulate embryo growth and development during implantation [71–73]. Moreover, a pivotal role in the regulation of embryo development and trophoblast growth is played by immune cells lodged in the endometrial stroma and in the decidua (Table 1).

Of note, the CD56^{bright} cells derived by NK circulating cell population and Treg cells also play a fundamental role in promoting the immune acceptance of semi-allogenic embryo by maternal immune system, as well as the HLA-G proteins located on trophoblast cells [82,93,94]. In particular, G-CSF and GM-CSF seem to play a direct role in Treg recruitment in the decidua/trophoblast interface, as well as regulating embryo development [81,82]. In this context, the endometrial epithelial cells secrete nano-sized EVs containing proteins and miRNAs [95]. miRNAs are a key element of the communication systems established between the mother and developing embryo and they play a crucial role in regulating hESC self-renewal/pluripotency and embryo development, and some hESC-specific miRNA genes are organized in clusters that represent key regulatory networks conserved in mammals [96]. The evidence that zygote and mature oocyte have similar miRNA profiles suggests that many zygotic miRNAs are maternally inherited [97]. However, miRNome pattern changes immediately after the first embryo division, where 60% of miRNAs are downregulated at the 2-cells stage [47,97]. Moreover, miRNAs are secreted into the extracellular environment by the embryo during the entire free-living stage of development from the 1-cell zygote to blastocyst to ensure cell-to-cell communication for self-organization process of embryonic development [98] (Figure 1). These miRNAs have been demonstrated to circulate in the body in proper packing of EVs required for stable transport [99]. Recent studies of EVs-miRNA profiling reveal specific miRNAs associated with embryo competence (Table 2).

The precision and the timing of such epigenetic processes are pivotal for avoiding developmental defects or embryo death [110,111]. Around 5–6 days post-fertilization, late blastocyst attaches to and invades the endometrial lining of the uterus. This process, known as implantation, marks the beginning of a complex dialogue between the embryo and the mother, an early milestone for pregnancy establishment and maintenance [112]. Implantation necessitates of a finely tuned synchrony between embryo and endometrium [113]. This synchronization occurs during a temporally restricted period (6–12 days post fertilization) known as “window of implantation” (WOI) and ovarian estrogens and progesterone primarily drive this sensitive stage [113,114].

Table 1. Decidua key factors involved in embryo development.

Class	Factor	Role in embryo development	Ref.
Cytokines and Growth Factors	IL-6	Support of trophoblast invasion and adhesion	[74]
	IL-10	Support of trophoblast functions and angiogenesis Promotes maternal-fetal crosstalk	[75,76]
	IL-8	Support of trophoblast invasion and spiral artery transformation	[77,78]
	TNF- α	Support of trophoblast invasion and interactions with maternal immune cells	[79]
	VEGF	Angiogenesis promotion	[80]
	G-CSF	Promote trophoblast invasion and Treg recruitment	[81]
	GM-CSF	Promote embryo growth and immunomodulation	[82]
	Nutrient transporters	GLUT-1	Provides glucose to the developing embryo
LAT-1		Ensures supply of essential amino acids to the embryo	[84]
Hormones	Progesterone	Regulates trophoblast invasion Creates a receptive environment for the embryo	[85]
	Estrogens	Promote cell growth and survival, modulate immune responses, influence placental development	[86]
	Prolactin	Supports stromal cell differentiation and immune modulation	[87]
miRNAs	let-7 family	Regulates decidualization process	[88]
	miR-290 cluster	Regulates decidualization process, support embryo implantation	[89]
	miR-21	Regulates inflammatory response, inhibit decidual cell apoptosis	[90]
	miR-16	Regulates angiogenesis	[91]
	miR-30c	Supports trophoblast development and endometrial receptivity	[92]

Table 2. Human EVs-derived miRNAs involved in embryo development.

Name	Target	Detection	Function	Ref.
miR-451	Wnt	Follicular fluid	Cell fate determination	[100,101]
miR-214	PTEN	Follicular fluid	Cell growth	[102,103]
miR-145	Abca1	Follicular fluid	Cholesterol levels	[102,104]
miR-454	EPHB4	Follicular fluid	Cell growth, apoptosis	[102,105]
miR-888	E-Cadherin	Follicular fluid	Cell growth	[102]
miR29a-3p	DNMT3A	Blastocoel fluid	Chromatin organization	[106]
miR-26a-5p	DNMT3B	Blastocoel fluid	Chromatin organization	[106]
miR-342-3p	HDAC9	Blastocoel fluid	Chromatin organization	[106]
miR-381	SRSF11	Blastocoel fluid	Stemness	[106,107]
miR-27a	HOXA	Serum	Cell differentiation	[108,109]

During WOI, the endometrium undergoes extensive structural and molecular remodeling. Adhesion molecules, cytokines, growth and transcriptional factors are just a few of endometrium-expressed molecules that collectively allow late blastocyst attachment and trophoblast invasion [115]. They are further supported by the immune tolerance establishment which avoids the rejection of the semi-allogeneic embryo [116]. Any change in the temporal alignment significantly compromises the success of embryo implantation [73], highlighting the need for fine regulated molecular pathways.

Emerging data ascribes to epigenetics an essential role in orchestrating early gestational events. Among epigenetic modifications, DNA methylation is involved in regulating implantation as well as endometrial transition to a receptive state [117,118].

Methylation modulates the expression of endometrial key genes involved in tissue remodeling and immune tolerance [119]. For instance, the hypomethylation of key transcription factors, among all HOXA10, HOXA11, and FOXO1, is critical for establishing a receptive endometrial environment, regulating the transcriptional activity of genes involved in cellular adhesion (e.g., E-cadherin, Integrin β 3), immune modulation (e.g., LIF), and hormonal response capability [120].

RNA methylation has recently emerged as a noteworthy epigenetic modification regulating gene expression for endometrial receptivity and embryo implantation [41]. In particular, m6A dynamically controls mRNA stability, splicing, and translation, thereby affecting cell differentiation and tissue

remodeling [121]. Actually, the dysregulation of m6A writers (e.g., METTL3) impairs blastocyst attachment and trophoblast invasion [41]. Shifting the focus to the endometrium, m6A allows the expression of genes involved in immune modulation and decidualization (transformation of endometrial stromal cells into highly specialized decidual cells) [41]. A recent study identified the METTL3–EED–YTHDC1 regulatory axis as a linker between m6A and H3K27me3 histone modification, affecting the accessibility of chromatin and the transcription of receptivity-related genes [122]. Moreover, m6A readers (e.g., FXR1) may also interact with DNA demethylation pathways, suggesting an aligned epigenetic landscape [123]. Overall, aberrant m6A signaling has been associated with recurrent implantation failure and reproductive disorders [124].

Likewise, increasing attention has been directed to the role of ncRNAs, which have emerged as master regulators of both embryonic competence and endometrial receptivity, thanks to their ability to fine-tune gene expression [125,126]. These molecules, including miRNAs, lncRNAs, and piRNAs, influence a wide range of biological pathways involved in the complex and synchronized process of embryo implantation, such as immune modulation and tolerance, embryo-endometrium crosstalk, and decidualization [127]. Table 3 reports the main ncRNAs whose up- or down-regulation controls endometrial receptivity and embryo implantation grouped depending on the molecular pathway to which the target genes belong.

For instance, a subset of ncRNAs results upregulated during the WOI and modulates the expression of cell adhesion

molecules like E-cadherin and integrin $\beta 3$ (e.g., miR-192-5p) [130]. Other ncRNAs, such as miR-125b, have been implicated in modulating LIF-STAT3 signaling and immune tolerance, both essential for a receptive environment [132].

Several ncRNAs target the HOX genes encoding for a family of transcription factors involved in the expression of key downstream effectors, including integrins, insulin-like growth factors and cytokines [132,137]. Although less studied, piRNAs are believed to contribute to genomic stability and epigenetic regulation in endometrial cells [153]. Collectively, the intricate network of ncRNAs ensures the precise coordination of molecular events required for successful pregnancy. The epigenetic modulation continues throughout the whole gestation with changes to the fetal and maternal methylome and the specific action of the ncRNA system, ensuring pregnancy maintenance and appropriate termination of gestation [111]. For instance, DNA methylation patterns in the placenta change dynamically to regulate genes involved in nutrient transport and immune tolerance. In the fetus, methylation of genes like *IGF2* is essential for proper growth and development [155,156]. Meanwhile, ncRNAs help pregnancy to reach healthy term by silencing genes that could trigger premature labor and support placental functions (e.g., miR-210) [111,155].

Although outside the primary scope of this review, as gestation progresses the bidirectional communication becomes more complex, involving a dynamic interplay between maternal and

fetal growing tissues. In this context, factors deriving from the placenta play a pivotal role in modulating maternal immunological tolerance, vascular remodeling, and metabolic balance to support fetal development and complete pregnancy [157]. Key milestones include the establishment of a functional placental architecture, the regulation of transplacental nutrients and gas exchange, and the fine-tuning of fetal gene expression in response to both maternal and environmental directions [158]. Overall, these interactions are tightly regulated by epigenetic mechanisms that ensure developmental plasticity and at the same time preserve genomic stability [157]. Disruptions in this finely tuned regulation have been associated with pregnancy complications such as intrauterine growth restriction and pre-term birth [158].

1.3. Inter- and trans-generational inheritance

An additional level of maternal-fetus crosstalk includes the transmission of epigenetic markers and clinical phenotypes from one generation to the next without changes in the primary sequence of DNA ascribing to the whole process a sort of heritability.

Epigenetic inheritance, by investigating the transfer of non-genetic traits or information from one generation (e.g., mother, *F0*) to the next (e.g., fetus, *F1*, and/or offspring *F2-Fn*), is attracting enormous interest in the scientific community

Table 3. Human ncRNAs involved in ZGA, endometrial receptivity, and embryo implantation.

ncRNA Type	Name	Target	Molecular pathway	Function	Ref.	
miRNAs	miR-34c	Maternal Bcl2	Cell death	ZGA	[128]	
	miR-302/367 cluster	OCT4, SOX2, NANOG	Pluripotency	ZGA	[128,129]	
	miR-17	E2F1, PTEN	Cell cycle	ZGA	[128]	
	miR-92	E2F1, PTEN		ZGA	[128]	
	miR-192-5p	E-cadherin	Cell adhesion	ER	[130]	
	miR-491-3p	Integrin $\beta 3$		ER	[131,132]	
	miR-1910-3p	Integrin $\beta 3$		ER	[131,132]	
	miR-183-5p	CTNNA2	Immune response	ER/EI	[133]	
	miR-124-3p	IL-6, IL-11		ER	[134]	
	miR-21-5p	IL-1 β		ER/EI	[135]	
	miR-125b	LIF		ER	[132]	
	miR-135a	HOXA10	Transcription	ER/EI	[136]	
	miR-135b	HOXA10		ER/EI	[132,137]	
	miR-145	IGF1R	Cell growth	EI	[132,138]	
	miR-27a	IGF1		ER	[132,139]	
	miR-449c	IGFBP1	Angiogenesis	ER	[140]	
	miR-17-5p	VEGF		ER	[114,141]	
	miR-16-5p	VEGF		ER	[142]	
	OIP5-AS1	HuR		mRNA stability	ZGA	[143]
	lncRNAs	lncRNA-FTX	E-cadherin, Vimentin	Cell adhesion	ER	[144]
LINC473		FOXO1, HOXA10	Transcription	ER	[126,145]	
lncRNA-RASA3		RASA3	Cell growth	ZGA	[146]	
lncRNA-TCL6		EGFR, AKT		ER	[147]	
lncRNA-STAT3-AS		STAT3		EI	[148]	
lncRNA-TCL1		TUNAR		EI	[148]	
TCONS_01729386		VEGF	Angiogenesis	ER	[126,149]	
TCONS_01325501		VEGF		ER	[126,149]	
piRNAs		PIWIL2 (HILI)	IL-10	Immune response	EI	[150,151]
		piR-36743	HOXA10	Transcription	ER	[152]
	piR-823	DNMT3B, HSP27		ER	[152]	
	piR-55490	AKT	Cell growth	EI	[153]	
	uniq_277797	FXR1		EI	[154]	
	uniq_271431	DDX6		EI	[154]	
	piR-55490	mTOR	Angiogenesis	EI	[153]	

Abbreviations: ZGA: zygote-genome-activation; ER: endometrial receptivity; EI: embryo implantation.

due to the broad translational applicability of the underlying knowledge. The mechanistic understanding of the basic processes of transmission and maintenance of environmental information to subsequent generations is of crucial importance also in helping the design of novel epidrug strategies [159–161]. This is because in many instances epigenetic processes may prevail, or strongly cooperate, over the direct genetic trait in the expression of phenotypes or diseases across generations, including protective mechanisms against several complex conditions [162,163].

The concept of heritable “epigenetic-based memory” of a phenotype has been investigated across diverse species. Plant studies revealed that key pathways are regulated via epigenetic modifications in response to environmental and/or biotic stressors to mitigate the trauma effects, maintain and transmit stress memory, or improve resilience [164,165]. Although the epigenetic effectors have long been identified (e.g., DNA methylation, histone acetylation, ncRNAs), and stress-exposed plants appear to be susceptible to epigenetic modifications resulting into transgenerational plasticity, there is still missing knowledge on the dynamics of the epigenetic marks establishment and on their stability [165,166]. Studies in animal models confirm that various epigenetic mediators (e.g., ncRNAs including miRNAs and piRNAs) respond to environment, and that their altered signature in germ cells may impact on offspring phenotype [167,168]. However, in mammals, and in particular in humans, the epigenetic-based inheritance of a phenotype is still a matter of debate, and up to now there is a larger agreement on inter- rather than transgenerational inheritance [168,169]. The interest in understanding the effect on health of offspring after parental exposure is growing, since it represents a novel view in modern biomedicine with strong translational potential [170]. A recent work reviewed the current evidence supporting the epigenetic inheritance of parental exposures in several detrimental contexts such as metabolic diseases, stress and trauma, toxicants, as well as in utero exposures, up to the experience of positive factors, to highlight the contribution of epigenetic traits [171]. Although there is strong evidence of “association,” there are still challenges and limitations to ascertain a proper epigenetic-inheritance mechanism in humans, including the demonstration of germline involvement [171].

The maternal effect, that is the in-utero influence of maternal phenotype, and/or genotype, on the phenotype of progenies, independently of their genotypes, belongs to the field of transgenerational epigenetics. During early development in humans, and mammals in general, the intimate role of the mother is the principal reason why she has the greatest chance to shape the developing individual [172]. Starting from zygote conception to delivery, pregnant females have the possibility to weave a mutual exchange of molecular messages with the fetus influencing its development, as well as the health and disease of both [172]. Epigenetic crosstalk between mother and embryo is constantly active and continues even after MZT, which is when it starts to synthesize its own proteins, enzymes, hormones, and ncRNAs, until the late phases of gestation when the mutual cooperation endures.

Although, the most deeply investigated epigenetic marks are methylation and acetylation of DNA or histones, other crucial mechanisms for transmitting information across generations exist, as small ncRNAs, prions, lipids, or microbiome. Interestingly, the crosstalk continues after birth, through tRNA-derived RNAs and miRNAs with gene silencing functions in the mother’s milk that can be transmitted from mom to baby and are involved in its immune health and development [172–175].

In general, the biological reason of why organisms transmit non-genetic information across generations is that epigenetic inheritance can transmit past/present environmental information to the descendants, allowing future generations to revert to the ancestral condition when the environmental stressor has passed. Basically, they have been proposed two distinct types of epigenetic transmission in response to the environmental insult based on the persistence and duration of their effect: intergenerational and transgenerational inheritance [173,176].

Intergenerational effects represent any consequence of parental (F_0) stress on F_1 progeny that either directly acts on or is communicated through F_0 germ cells or developing F_1 embryos in utero. Transgenerational effects are those initiated in the F_0 generation and persisting into F_3 or later (F_n) generations. However, effects that started in F_0 and persist in F_2 generation are categorized intergenerational when germ cells of F_1 were in utero at the time of event/stress action and transgenerational if no F_1 germ cells had been formed.

Apart from this general distinction, a great controversy exists on the definition of the maternal-fetus transmission of such non-Mendelian traits. In order to clarify this point and give a clear description of the epigenetic involved mechanisms and transmission we should consider some important details.

When adult mammals are exposed to external stressors, the entire body components, that are somatic cells, germline cells, as well as germline of the fetus in pregnant females, are directly exposed to the potential epigenetic modifications. They all belong to the same generation (F_0) of exposed individuals and in the successive generations (i.e., F_1 of exposed males or exposed non-pregnant females), observable phenotypes or epigenetic marks cannot strictly presume any kind of inheritance. Similarly, an exposed pregnant female gathers under the same F_0 generation the successive F_1 and F_2 . Then, we consider both these scenarios as intergenerational effect (commonly described as intergenerational inheritance), that is the transmission and maintenance of a same observable epigenetic mark previously acquired at the time of F_0 exposure. Applying the same rationale, transgenerational inheritance can be found in F_2 or later F_n of exposed males or non-pregnant females, and in F_3 or later F_n of exposed pregnant females (Figure 2).

For the reasons above described, it seems that a true epigenetic inheritance is difficult in mammals, and virtually impossible in humans, also considering that DNA methylation is globally reduced twice in each generation closely after fertilization and during the developing PGCs as detailed above. Accordingly, flaws in *DNMTs* genes, as *DNMT1* for methylation maintaining, or *DNMT3A* and *DNMT3B* for de-




Figure 2. Intergenerational and transgenerational epigenetic inheritance. If a gestating mother (F0, left) is directly exposed to stressors, exposure may affect also the developing fetus and his/her developing germ line (green), resulting in intergenerational effect (possible inheritance) in F1 and F2 generations. F3 generation is the first non-directly exposed and an observed phenotype could be the result of transgenerational epigenetic inheritance. If a male or a non-pregnant female (F0, right) are directly exposed to stressors (for female exposure would occur before conception), germ cells may also be affected influencing F1 generation. F2 generation would be the first not directly exposed and appearance of the phenotype in F2 could be the result of transgenerational epigenetic inheritance. Created in BioRender. Tisato, V. (2025) <https://biorender.com/e2brw4i>.

novo methylation, or in *TETs* genes, as *TET1*, *TET2* and *TET3*, involved in DNA demethylation, by affecting (re-)establishment or erasing of the epigenetic marks in the specific (hemi)-genome may contribute to epigenetic inheritance in mammals [177]. In humans, any environmental induced epimutation to be considered as transgenerationally inherited should evade the epigenetic reprogramming in the PGCs and in the developing embryo after fertilization, subsequently they should be transmitted to the offspring, and persist in unexposed individuals [178]. This challenge has started a long-standing debate about the possibility of inheriting acquired traits, which has been strongly questioned since the Lamarckian and Darwinian eras. Another challenge is the lack of consensus in the definition of transgeneration in humans. A recent paper in 2024 called the question and proposed five essential elements and criteria to confirm transgeneration [179]: (i-ii) *inheritance of phenotypes (i) or epigenetic marks (ii) by the first unexposed generation induced by environmental factor(s) applied to the F0 generation*; (iii) *inheritance of the same epimutation(s) across generations*; (iv) *gene expression changes in subsequent generations*; (v) *germ cells tested in each generation* [179]. Although restrictive, they do not rule out transgenerational inheritance in humans, but they make it difficult to detect in research studies. On the other hand, also small ncRNAs, particularly tRNA-derived small RNAs (tsRNAs), and miRNAs have been proposed as emerging mediators of environmental information transmission through gametes in mammals. In detail, sperm-delivered sncRNAs may transmit

paternally acquired traits to offspring, modulate zygotic gene expression and influence early embryonic development, broadening the range of actors involved in the process [180,181].

Although most studies on epigenetic inheritance mainly consider DNA methylation [178,182] or ncRNA [183,184], few have examined histones or multiple processes. Accordingly, previous studies demonstrated a role for ncRNAs in RNA-directed DNA methylation in several different systems [185–187]. Similarly, altered DNA methylation, ncRNAs, and differential histone retention sites and histone modifications suggested crucial interactions and integrations between the different epigenetic processes [188,189]. As an example, histones can be modified by ncRNAs and chromatin remodeling can start the transition from active euchromatin and gene expression to inactive heterochromatin [190]. Even though evidence is available on histone retention in sperm and its impact on the embryo [191,192], the role of specific epigenetic processes in histone retention has not been reported. Finally, environmental exposures promoting transgenerational epigenetic inheritance of sperm histone retention have been described [188,189,193]. Interestingly, a model of *C. Elegans*, to translate into human obesogenity, investigating how lipid accumulation leads to signals that pass across generations, authors demonstrated that such signals might be transgenerationally transmitted to progeny [194]. Authors identified histone H3K4me3 as a contributing actor in obesity, though the function of DNA methylation and ncRNAs remains unclear.

Summarizing, DNA methylation, ncRNAs, and histone modifications mutually integrate in the occurrence of epigenetic transgenerational inheritance.

Furthermore, whereas transgenerational epigenetic inheritance has been widely documented in plants, worms, and fruit flies, analogous evidence in mammals remains debated, though several investigations in mice models support some evidence [179,195]. For instance, growth at elevated temperature in *C. Elegans* or in *D. Melanogaster* activates the expression of a subset of endogenous repetitive elements, normally repressed, which may require several generations to be fully restored [196,197]. On the contrary, in humans to confirm epigenetic changes we need to detect them at least up to F3 mainly because of the two waves of epigenetic reprogramming.

Other factors that may influence epigenetic inheritance in mammals are some “confounding factors” such as a direct maternal contribution due to non-optimal in utero conditions, as well as paternal influences mainly due to aberrant components of the seminal fluid. Moreover, postnatal effects, lifestyle or genetic predispositions, may act as the main origin of the observed modified epigenetic or phenotypic trait in the progeny.

For the reasons above described the mother’s womb and the in-utero microenvironment are of crucial importance for a correct embryo epigenetic development and future newborn health. Accordingly, there are sensitive crucial phases of life during which the maternal effect strongly may impact on the baby health and development. In detail, all this may potentially be transmitted and have an impact on behavior, cognition, and immune system development of the future individual [198–200]. Globally, from zygote conception to the age of two years this frame includes a critical window called the first 1000 days of life, where an appropriate development of fetus is put in place to allow the child an healthy and epigenetically updated development [201].

As reported by the Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS), offspring might epigenetically suffer the maternal in utero milieu during fetus development and several complex diseases as leukemia, blastoma, or neurodevelopmental disorders can appear during childhood life [202–204]. An extreme consequence of abnormal epigenetic maternal environment can even lead to early pregnancy loss by altering blastocyst implantation or embryo development disturbing the perfect endometrial-embryo synchronization as described above [205,206]. However, the restricted number of investigations in humans is the limiting step, nevertheless it may be bypassed by the presence of several animal studies supporting the transmission of acquired traits across generations [207–209]. Finally, to definitely ascribe and demonstrate epigenetic-mediated mechanisms in human inheritance, there is the need of a rigorous methodology and the systematic investigation of several generations as recently proposed [210,211].

In conclusion, transgenerational epigenetic inheritance in humans is limited but possible, and a fine tuning and mutual synergy between genetics and epigenetics may be the true balance in determining this action. By complementing data from GWAS with EWAS may help us in identifying on the one

hand the specific trajectory of epigenetic inheritance and on the other hand the relative contribution of genome and epigenome in transgenerational mechanisms [4].

Regardless of the apparent molecular transfer of epigenetic messages, the direct effect of the mother to the baby, by womb milieu and/or after birth, acts as the first epigenetic treatment the mother directly fix on her progeny according to her own coping toward environment.

1.4. Curable epigenome: is there a role for epidrugs in reproductive medicine?

The term “curable epigenome” refers to the possibility of targeting alteration of the epigenome to correct acquired epigenetic marks associated with pathological phenotypes, which may be either the cause of the development or progression of several diseases, such as cancer, metabolic diseases, and neurodegenerative disorders [161,212–214]. The discovery that complementary epigenetic-modifying enzymes may be useful to target and reverse epigenetic modifications, has opened the road for suitable epidrugs applications toward those proteins involved in epigenetic regulation [215]. Although they were initially developed mainly for the treatment of tumors, such as azacitidine (the first FDA approved for the treatment of myelodysplastic syndrome [216]), interest in their therapeutic potential has increased significantly over time in numerous branches of medicine. In particular, the identification of specific associations between epigenetic marks and male/female infertility, of the role of epigenome in the plasticity of embryo development, and of epigenetic signatures in reproductive-related disorders such as endometriosis [217–219], have increased the relevance of epigenetics as therapeutic target and of epidrugs as innovative therapeutic tool.

Based on their enzymatic function and target, epidrugs can be classified into: DNA methyltransferase inhibitors (DNMTi), histone deacetylases inhibitors (HDACi), and histone methyltransferase inhibitors (HMTi) [220,221]. DNMTi include agents such as 5-azacitidine and decitabine that have been initially developed for the treatment of hematological malignancies. These, by interfering with DNA methylation (e.g., hypomethylating actions) lead to gene expression changes and potential differentiation of myeloid cells. DNMTi inhibit the activity of DNMTs by acting as nucleoside or non-nucleoside analogues, causing overall global DNA demethylation and consequent reactivation of pathologically silenced genes (e.g., tumor suppressor genes in cancer cells) [222,223]. In reproductive medicine, DNMTi may target aberrant hypermethylation associated with defects in gametogenesis or embryonic development that contribute to unsuccessful reproduction, restoring a physiological methylation pattern. HDACi, such as vorinostat (SAHA) or valproate, can block the activity of histone deacetylases, that remove acetyl groups from histones leading to a reduction in transcriptional activity. This inhibitor action makes chromatin more accessible to transcription factors and promotes gene expression [224,225]. In reproductive medicine, HDACi can be used to improve the quality of gametes or embryos, increasing the transcription of genes essential for their correct development, counteracting in turn the negative

effects of environmental stressors on chromatin [226]. HDACi may act as potential therapeutic tool in the treatment of ovarian or endometrial dysfunctions [227]. Similarly, HMTi can modulate histone methylation by inhibiting HMTs enzymes that add methyl groups to specific lysine or arginine residues on histones. The overall effect depends on the specific location and number of methylation sites, and these processes may result in activation or global repression of gene transcription [228]. In this perspective, several substances, such as inhibitors of EZH2 (an HMT involved in the methylation H3K27me3), have been shown to be able to modulate gene expression and for this reason, they are deeply investigated for clinical use [225]. Due to its complex and multiple roles in gene expression, modulation of histone methylation may efficiently tune epigenetic defects improving in turn global reproductive health [229].

The potential of epidrugs in reproductive medicine includes their use to improve the quality of spermatozoa and oocytes, both *in vivo* and *in vitro*. Gametogenesis is a very complex process and sensitive to stress and environmental factors which can induce epigenetic abnormalities. For this reason, low doses of DNMTi or HDACi could be used to correct possible alterations, allowing the production of competent gametes for successful fertilization, improving morphology, motility, DNA integrity, and embryonic development [230–232]. In confirmation of this, it has been demonstrated that an inadequate intake of folates and vitamins B6 or B12 (considered natural epidrugs) is associated with anovulation and fertility reduction [233]. As regards embryogenesis, the use of folic acid and vitamin B12 during pregnancy has been widely accepted for years with the aim of improving cell replication, especially in periods of active cell duplication, maintaining the correct epigenetic setting (i.e., faithful DNA replication and stability) and consequently increasing the chance of healthy offspring [234–236]. ART procedures, such as controlled ovarian stimulation and prolonged embryo culture, may in turn induce epigenetic alterations in embryos [237,238]. A recent study aimed at fulfilling the gap in knowledge of ovarian stimulation or blastocyst culture with adverse health outcomes or imprinting disorders in offspring did not reveal strong negative results. By EWAS of blastocysts obtained after superovulation of young or adult mice compared with blastocysts derived from non-stimulated mice, authors found a minimal effect of ovarian stimulation on the DNA methylation but a greater impact of *in vitro* growth and maturation of oocytes [239].

Theoretically, the addition of epidrugs in embryo culture media at precise timing could mitigate possible negative effects by promoting physiological epigenetic reprogramming. This could lead to increased implantation capacities, reduced risk of epigenetic abnormalities in embryos and ultimately increased full-term pregnancy rates. Hypotheses are widely supported by studies that have correlated the intake of folic acid and vitamins B6 and B12 with a better quality of oocytes and embryos and with a greater probability of successful pregnancies [233]. Even in the case of transgenerational transmission of pathological epigenetic phenotypes, epidrugs could have the potential to erase or correct aberrant epi-

modifications, interrupting the chain of transmission of possible pathological phenotypes [240]. Moreover, among the acquired conditions that affect the individual epigenome, it is important to consider the effects on sperm or oocyte of cancer survivors after chemotherapy cycles. Theoretically, acquired modifications of the gamete epigenome can be transmitted to the offspring, although cryopreservation of gametes before treatment may represent an opportunity to be considered while waiting for effective and safe treatments with epidrugs [241–244].

In recent years, the potential of epidrugs has been reported for the treatment of female reproductive disorders, including polycystic ovary syndrome (PCOS) and endometriosis. PCOS is a heterogeneous condition characterized by a clear epigenetic component, mainly alterations in DNA methylation and presence of histone modifications in oocytes, granulosa cells, and endometrial tissues that overall result in altered gene expression. Epidrugs may improve these altered gene expression profiles by acting on insulin sensitivity, inflammation, or ovarian steroidogenesis [245]. Endometriosis, a chronic inflammatory disease, is characterized by the presence outside the uterus of endometrial tissue with altered DNA methylation pattern and aberrant histone modifications, which promote growth, survival, and invasiveness of endometrial lesions and may serve as a target for new therapeutic strategies complementary/alternative to current ones [246].

Beyond gametes quality, proper early embryonic development is also essential for a successful pregnancy and the production of healthy offspring. As above reported, we are describing a complex and finely regulated process in which alterations of key pathways may result in perturbation of embryo implantation, development, and viability. It has to be noted that although epidrugs in relation to embryo development has mainly focused on the potential teratogenic effects of compounds, the potential of targeting epigenetic marks as a new strategy to improve early embryonic development, particularly in ART, is attracting more interest. Several preclinical studies report on the use of epidrugs to correct alterations in the embryonic epigenome and improve embryo quality and competence. For example, exposure to HDACi during *in vitro* culture of bovine embryos allowed efficient embryo survival after vitrification and reduced abnormal expression of paternal imprinted genes, suggesting that HDACi can reduce the negative effects on embryonic epigenome [247]. In the same line, Shao et al. analyzed the impact of HDACi (e.g., MGCD0103 and T247) in mouse embryo development reporting effect on ZGA via improved epigenetic regulation, supporting the potential use of HDACi in reproductive medicine [248].

Regarding DNA methylation during embryogenesis, while those mediated by TET proteins do not appear to be essential for gastrulation (i.e., TET knockout embryos exhibit normal gastrulation), overall DNA methylation by DNMTs is critical with embryos lacking DNMTs that do not gastrulate, unlike those with partial deficiency [249]. Consistently, analysis of the expression of DNMTs in the chorionic villi of pregnant women demonstrated their role in placenta, with DNMT3B showing the highest levels. Conversely, in the chorionic villi of those

women with early embryo growth arrest, DNMT3A protein was under-expressed. From this, it is deduced that inefficient maintenance of methylation, due to reduced DNMT3A levels, could cause abnormal embryonic development in early pregnancy [250]. Similarly, DNMT3B resulted crucial for embryonic development in a murine model and its absence led to Wnt and Hedgehog pathways deregulation and affected embryo development [251].

Bromodomain and Extra-Terminal Domain (BET) family proteins activate the expression of key genes such as *Nanog*, *Otx2*, and *Sox2*, and are essential for the formation and maintenance of the epiblast in preimplantation mammalian embryos [252]. In this line, BET protein inhibition (e.g., via JQ1), or bromodomain-containing proteins (BRD) deficiency, may significantly reduce *NANOG* expression. BRD inhibitors have been investigated in the modulation of oligodendrocyte progenitor cell differentiation, showing differential effects depending on the BRD target [253]. Their predominant role in early embryonic development relies on pluripotency and specific maintenance at the inner cell mass and epiblast lineages. Understanding how these proteins involved in epigenome preservation act on specific pathways and genes will enable the development of targeted approaches against infertility and developmental diseases. Table 4 shows epidrugs with biological targets investigated in diseases treatment and embryo development.

Despite their great potential, the study of epidrugs in reproductive medicine is still in its early stages and presents several challenges that need to be overcome before considering possible clinical use. First, it is necessary to improve specificity and reduce off-target effects. Current epidrugs, in fact, may lack the specificity needed to intervene on such delicate and complex processes as gametogenesis and embryonic development. Since they target a wide range of cellular processes, they may lead to unwanted or unpredictable side effects [262]. In the same line, establishing the correct drug dosage and the optimal schedule of administration are mandatory tasks [263]. An incorrect dosage or timing

could not only be ineffective but also cause irreversible damage or unwanted epigenetic alterations with severe long-term consequences. Furthermore, it is certainly not of secondary importance to minimize their cytotoxicity, especially for those cells in active replication, and identify the best delivery system [262,264]. Finally, a deeper understanding of the “normal” epigenome patterns of both gametes and embryonic cells is essential to overcome the current limited knowledge in this field, lessening the validation of interventions aimed at restoring optimal “physiological” epigenome conditions.

Certainly, the curable epigenome represents an exciting prospect also for human reproductive medicine. The growing understanding of the important role epigenome has in fertility, gametogenesis, and embryo development allows to identify new potential targets for precise therapeutic interventions. Epidrugs may have a considerable potential to improve the quality of gametes and optimize the efficacy of ART to treat specific reproductive diseases.

1.5. Future perspective

Epigenetics is a rapidly developing and expanding field that is shedding light on the mechanisms underlying a wide range of biological processes. Decoding epigenetic landmarks related to health and disease has therefore the enormous potential of changing both human disease prevention and treatment [265]. In the field of human reproduction, selective and specific epigenetic marks need to be established; exact timing and spatial windows have to be identified during gametogenesis, as well as in the early stages of embryogenesis, pregnancy establishment and maintenance. Although our knowledge on the role of the specific epigenetic signatures is significantly increased, the consequence of their dysregulation mainly relies on preclinical animal models while the outcome of embryonic and long-term human development still needs to be deeply investigated.

Table 4. Epidrugs tested for urogenital system disease treatment and embryo development improvement.

Epidrug(s)	Target	Class	Application	Ref.
KSK64, LAK31, MPK409, Romidepsin, Quisinostat	HDACs	HDAC inhibitors	Treatment of urological tumors, cisplatin-resistant germ cell tumors	[254]
ASK44, ASK58, ASK62, JQ1	BET proteins	BET inhibitors		
LAK-FFK11, LAK129, LAK-HGK7	HDACs	HDAC/BET inhibitors		
OTX015	BET proteins	BET bromodomain inhibitor	Ovarian cancer treatment	[255]
Vitamin C	Tet enzymes	Essential cofactor for TET protein activity	Influencing DNA methylation patterns and gene expression in ESC	[256]
Guadecitabine (G)	DNMTs	Nucleoside analogue, DNA hypomethylating agent	Recurrent platinum-resistant ovarian cancer	[257]
Decitabine	DNMTs	DNMT inhibitor	Treatment of male fertility	[258]
Vorinostat	HDACs	HDAC inhibitor		
GSK-J4	KDM6A/KDM6B demethylases	Histone demethylase inhibitor	Testicular germ cell tumors	[259]
5-aza	DNMTs	DNMT inhibitor	Cisplatin resistance in germ cell tumors	[260]
5-aza	DNMTs	DNMT inhibitor	Improvement of endometrial receptivity	[261]
GSK343	EZH2 enzyme	Histone methyltransferase inhibitor	Treatment of endometriosis	[229]
Scriptaid	HDACs	HDAC inhibitor	In vitro development of bovine embryos	[247]
MGCD0103 and T247	HDACs	HDAC inhibitor	Effect on early embryonic development (transcriptome level)	[248]

Abbreviations: HDACs: Histone deacetylases; BET: Bromodomain and Extra-Terminal Domain; Tet: Ten-Eleven Translocation; DNMTs: DNA methyltransferases; 5-aza-5-aza-2'-deoxycytidine.

Advances in epigenetics understandings are therefore rising crucial questions and implications. The role of epigenetic mechanisms in translating environmental signals (including negative experiences and trauma), highlights potential inter- or trans-generational inheritance of epigenetic marks that may influence health and disease in the offspring [266]. Although a clear causal association between exposure to stressors and transgenerational inheritance in humans is still to be completely certified, a recent report calls for consideration [210].

In the same line, the growing utilization of ART mainly due to a trend toward delayed childbearing and low fertility needs to be considered. Although ART procedures do not seem to have a significant effect on specific epigenetic changes [267], the sensitivity of the embryonic epigenome to environmental factors needs to be monitored in dedicated longitudinal studies to reveal the establishment of potential persistent epigenetic dysregulations in ART-conceived offspring [237,239,268].

Finally, as far as our understanding of the epigenetic mechanisms governing the mother-fetus crosstalk, it is to take into account that the same epigenetic marks may represent targets for potential therapeutic interventions. The theoretical principle underlying the use of epidrugs infers the existence of a “correct” epigenome that should be restored. In this line, the basic epigenetic drug discovery/development/repurposing has been until now mainly based on phenotypic observations [269,270]. This assumes that we know what the healthy phenotype is but we do not fully know what the “normal” epigenome is [271]. The increasing insights on epigenetic mechanisms underlying specific pathophysiological contexts and precise developmental stages is currently supporting a proper target-based approach [269]. Of note, epidrugs design needs also to consider the intrinsic flexibility of the epigenome and the reversibility of epigenetic marks, as well as the role of environment as key driver in the acquisition and maintenance of specific signatures [269,272]. Although this approach is still in its infancy, insights coming from other clinical contexts highlight the use of epidrugs to revert epigenetic disrupted processes and promote personalized treatments as stand-alone approaches or in combination with standard therapies [215].

Author contributions

Donato Gemmati: Conceptualization, Resources, Writing – original draft, Writing – review and editing, Visualization, Investigation, Supervision, Funding acquisition. Elisabetta D’Aversa: Investigation, Writing – original draft, Writing – review and editing. Francesca Salvatori: Investigation, Writing – original draft, Writing – review and editing. Marco Sbraccia: Investigation, Writing – original draft, Writing – review and editing.

Giuseppina Peluso: Investigation, Writing – review and editing. Fabio Scarpellini: Investigation, Writing – original draft, Writing – review and editing. Veronica Tisato: Conceptualization, Resources, Writing – original draft, Writing – review and editing, Visualization, Investigation, Supervision, Funding acquisition.

Disclosure statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with

the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Funding

Local grants from University of Ferrara: University Fund for Scientific Research (FAR), and Departmental Research Incentive Fund (FIRD) to Donato Gemmati and Veronica Tisato.

References

Papers of special note have been highlighted as either of interest (*) or of considerable interest () to readers.**

1. Waddington CH. The epigenotype. 1942. *Int J Epidemiol.* 2012;41(1):10–13. doi: [10.1093/ije/dyr184](https://doi.org/10.1093/ije/dyr184)
2. Waddington CH. Epigenetics and evolution. *Symp Soc Exp Biol.* 1953;7:186–199.
3. Van Speybroeck L. From epigenesis to epigenetics. *Ann N Y Acad Sci.* 2002;981(1):61–81. doi: [10.1111/j.1749-6632.2002.tb04912.x](https://doi.org/10.1111/j.1749-6632.2002.tb04912.x)
4. Cavalli G, Heard E. Advances in epigenetics link genetics to the environment and disease. *Nature.* 2019;571(7766):489–499. doi: [10.1038/s41586-019-1411-0](https://doi.org/10.1038/s41586-019-1411-0)
5. Greally JM. A user’s guide to the ambiguous word ‘epigenetics’. *Nat Rev Mol Cell Biol.* 2018;19(4):207–208. doi: [10.1038/nrm.2017.135](https://doi.org/10.1038/nrm.2017.135)
6. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet.* 2003;33(3):245–254. doi: [10.1038/ng1089](https://doi.org/10.1038/ng1089)
7. Jin B, Li Y, Robertson KD. Dna methylation: superior or subordinate in the epigenetic hierarchy? *Genes Cancer.* 2011;2(6):607–617. doi: [10.1177/1947601910393957](https://doi.org/10.1177/1947601910393957)
8. Smith ZD, Hetzel S, Meissner A. Dna methylation in mammalian development and disease. *Nat Rev Genet.* 2025;26(1):7–30. doi: [10.1038/s41576-024-00760-8](https://doi.org/10.1038/s41576-024-00760-8)
9. Turner BM. Histone acetylation and an epigenetic code. *Bioessays.* 2000;22(9):836–845. doi: [10.1002/1521-1878\(200009\)22:9<836::AID-BIES9>3.0.CO;2-X](https://doi.org/10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X)
10. Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. *Biochem Cell Biol.* 2005;83(3):344–353. doi: [10.1139/o05-041](https://doi.org/10.1139/o05-041)
11. Millan-Zambrano G, Burton A, Bannister AJ, et al. Histone post-translational modifications - cause and consequence of genome function. *Nat Rev Genet.* 2022;23(9):563–580. doi: [10.1038/s41576-022-00468-7](https://doi.org/10.1038/s41576-022-00468-7)
12. Wei JW, Huang K, Yang C, et al. Non-coding RNAs as regulators in epigenetics (review). *Oncol Rep.* 2017;37(1):3–9. doi: [10.3892/or.2016.5236](https://doi.org/10.3892/or.2016.5236)
13. de Sousa Lopes SM, Roelen BA, Monteiro RM, et al. Bmp signaling mediated by Alk2 in the visceral endoderm is necessary for the generation of primordial germ cells in the mouse embryo. *Genes Dev.* 2004;18(15):1838–1849.
14. Seydoux G, Braun RE. Pathway to totipotency: lessons from germ cells. *Cell.* 2006;127(5):891–904. doi: [10.1016/j.cell.2006.11.016](https://doi.org/10.1016/j.cell.2006.11.016)
15. Tang WW, Kobayashi T, Irie N, et al. Specification and epigenetic programming of the human germ line. *Nat Rev Genet.* 2016;17(10):585–600. doi: [10.1038/nrg.2016.88](https://doi.org/10.1038/nrg.2016.88)
16. Leitch HG, Tang WWC, Surani MA. Chapter five - primordial germ-cell development and epigenetic reprogramming in mammals. In: Heard E, editor. *Current topics in developmental biology.* Vol. 104. Academic Press; 2013. p. 149–187.

17. Lee SM, Surani MA. Epigenetic reprogramming in mouse and human primordial germ cells. *Exp Mol Med.* 2024;56(12):2578–2587. doi: [10.1038/s12276-024-01359-z](https://doi.org/10.1038/s12276-024-01359-z)
18. Messerschmidt DM, Knowles BB, Solter D. Dna methylation dynamics during epigenetic reprogramming in the germline and preimplantation embryos. *Genes Dev.* 2014;28(8):812–828. doi: [10.1101/gad.234294.113](https://doi.org/10.1101/gad.234294.113)
19. Zeng Y, Chen T. Dna methylation reprogramming during mammalian development. *Genes (Basel).* 2019;10(4):257. doi: [10.3390/genes10040257](https://doi.org/10.3390/genes10040257)
20. Suganuma T, Workman JL. Crosstalk among histone modifications. *Cell.* 2008;135(4):604–607. doi: [10.1016/j.cell.2008.10.036](https://doi.org/10.1016/j.cell.2008.10.036)
21. Chen Y, Wang L, Guo F, et al. Epigenetic reprogramming during the maternal-to-zygotic transition. *Med Comm.* 2023;4(4):e331. doi: [10.1002/mco2.331](https://doi.org/10.1002/mco2.331)
22. Zakar T, Paul JW. Fetal membrane epigenetics [Review]. *Front Physiol.* 2020;11:- 2020. doi: [10.3389/fphys.2020.588539](https://doi.org/10.3389/fphys.2020.588539)
23. Jeziorska DM, Murray RJS, De Gobbi M, et al. Dna methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease. *Proc Natl Acad Sci USA.* 2017;114(36):E7526–E7535. doi: [10.1073/pnas.1703087114](https://doi.org/10.1073/pnas.1703087114)
24. Wang Q, Xiong F, Wu G, et al. Gene body methylation in cancer: molecular mechanisms and clinical applications. *Clin Epigenet.* 2022;14(1):154. doi: [10.1186/s13148-022-01382-9](https://doi.org/10.1186/s13148-022-01382-9)
25. Kalish JM, Jiang C, Bartolomei MS. Epigenetics and imprinting in human disease. *Int J devbiol.* 2014;58(2–4):291–298.
26. Ramakrishna NB, Murison K, Miska EA, et al. Epigenetic regulation during primordial germ cell development and differentiation. *Sex Dev.* 2021;15(5–6):411–431. doi: [10.1159/000520412](https://doi.org/10.1159/000520412)
27. Zhou H, Hu S, Yan W, Yan W. Extracellular vesicles as modifiers of epigenomic profiles. *Trends Genet.* 2024;40(9):797–809. doi: [10.1016/j.tig.2024.05.005](https://doi.org/10.1016/j.tig.2024.05.005)
28. Vastenhouw NL, Cao WX, Lipshitz HD. The maternal-to-zygotic transition revisited. *Development.* 2019;146(11). doi: [10.1242/dev.161471](https://doi.org/10.1242/dev.161471)
29. Sha QQ, Zheng W, Wu YW, et al. Dynamics and clinical relevance of maternal mRNA clearance during the oocyte-to-embryo transition in humans. *Nat Commun.* 2020;11(1):4917. doi: [10.1038/s41467-020-18680-6](https://doi.org/10.1038/s41467-020-18680-6)
30. Hammoud SS, Nix DA, Zhang H, et al. Distinctive chromatin in human sperm packages genes for embryo development. *Nature.* 2009;460(7254):473–478. doi: [10.1038/nature08162](https://doi.org/10.1038/nature08162)
31. Casas E, Vavouri T. Sperm epigenomics: challenges and opportunities. *Front Genet.* 2014;5:330. doi: [10.3389/fgene.2014.00330](https://doi.org/10.3389/fgene.2014.00330)
32. Kobayashi H, Sakurai T, Imai M, et al. Contribution of intragenic DNA methylation in mouse gametic DNA methylomes to establish oocyte-specific heritable marks. *PLOS Genet.* 2012;8(1):e1002440. doi: [10.1371/journal.pgen.1002440](https://doi.org/10.1371/journal.pgen.1002440)
33. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. *Science.* 2001;293(5532):1089–1093. doi: [10.1126/science.1063443](https://doi.org/10.1126/science.1063443)
34. Smith ZD, Chan MM, Mikkelsen TS, et al. A unique regulatory phase of DNA methylation in the early mammalian embryo. *Nature.* 2012;484(7394):339–344. doi: [10.1038/nature10960](https://doi.org/10.1038/nature10960)
35. Guo H, Zhu P, Yan L, et al. The DNA methylation landscape of human early embryos. *Nature.* 2014;511(7511):606–610. doi: [10.1038/nature13544](https://doi.org/10.1038/nature13544)
36. Greenberg MVC, Bourc'his D. The diverse roles of DNA methylation in mammalian development and disease. *Nat Rev Mol cell Biol.* 2019;20(10):590–607. doi: [10.1038/s41580-019-0159-6](https://doi.org/10.1038/s41580-019-0159-6)
37. Schulz KN, Harrison MM. Mechanisms regulating zygotic genome activation. *Nat RevGenet.* 2019;20(4):221–234. doi: [10.1038/s41576-018-0087-x](https://doi.org/10.1038/s41576-018-0087-x)
38. Asami M, Lam BYH, Ma MK, et al. Human embryonic genome activation initiates at the one-cell stage. *Cell STEM Cell.* 2022;29(2):209–216.e4. doi: [10.1016/j.stem.2021.11.012](https://doi.org/10.1016/j.stem.2021.11.012)
39. Yuan S, Zhan J, Zhang J, et al. Human zygotic genome activation is initiated from paternal genome. *Cell Discov.* 2023;9(1):13. doi: [10.1038/s41421-022-00494-z](https://doi.org/10.1038/s41421-022-00494-z)
40. Best JD, Carey N. The epigenetics of normal pregnancy. *Obstet Med.* 2013;6(1):3–7. doi: [10.1258/om.2011.110070](https://doi.org/10.1258/om.2011.110070)
41. Wu S, Xie H, Su Y, et al. The landscape of implantation and placentation: deciphering the function of dynamic RNA methylation at the maternal-fetal interface. *Front Endocrinol (Lausanne).* 2023;14:1205408. doi: [10.3389/fendo.2023.1205408](https://doi.org/10.3389/fendo.2023.1205408)
- **Comprehensive review of the role of the dynamic RNA methylation at the maternal-fetal interface influencing embryo development, implantation and endometrial receptivity.**
42. Singh A, Rappolee DA, Ruden DM. Epigenetic reprogramming in mice and humans: from fertilization to primordial germ cell development. *Cells.* 2023;12(14):1874. doi: [10.3390/cells12141874](https://doi.org/10.3390/cells12141874)
43. Wilkinson AL, Zorzan I, Rugg-Gunn PJ. Epigenetic regulation of early human embryo development. *Cell STEM Cell.* 2023;30(12):1569–1584. doi: [10.1016/j.stem.2023.09.010](https://doi.org/10.1016/j.stem.2023.09.010)
44. Shahbazi MN, Pasque V. Early human development and stem cell-based human embryo models. *Cell STEM Cell.* 2024;31(10):1398–1418. doi: [10.1016/j.stem.2024.09.002](https://doi.org/10.1016/j.stem.2024.09.002)
45. Xia W, Xu J, Yu G, et al. Resetting histone modifications during human parental-to-zygotic transition. *Science.* 2019;365(6451):353–360. doi: [10.1126/science.aaw5118](https://doi.org/10.1126/science.aaw5118)
46. Wu K, Fan D, Zhao H, et al. Dynamics of histone acetylation during human early embryogenesis. *Cell Discov.* 2023;9(1):29. doi: [10.1038/s41421-022-00514-y](https://doi.org/10.1038/s41421-022-00514-y)
47. Paloviita P, Hyden-Granskog C, Yohannes DA, et al. Small RNA expression and miRNA modification dynamics in human oocytes and early embryos. *Genome Res.* 2021;31(8):1474–1485. doi: [10.1101/gr.268193.120](https://doi.org/10.1101/gr.268193.120)
48. Leonardo TR, Schultheisz HL, Loring JF, et al. The functions of microRNAs in pluripotency and reprogramming. *Nat cellbiol.* 2012;14(11):1114–1121. doi: [10.1038/ncb2613](https://doi.org/10.1038/ncb2613)
49. Paloviita P, Vuoristo S. The non-coding genome in early human development - recent advancements. *Semin Cell devbiol.* 2022;131:4–13.
50. Renfree MB, Fenelon JC. The enigma of embryonic diapause. *Development.* 2017;144(18):3199–3210. doi: [10.1242/dev.148213](https://doi.org/10.1242/dev.148213)
51. Fenelon JC, Banerjee A, Murphy BD. Embryonic diapause: development on hold. *Int J devbiol.* 2014;58(2–4):163–174.
52. van der Weijden VA, Ulbrich SE. Embryonic diapause in roe deer: a model to unravel embryo-maternal communication during pre-implantation development in wildlife and livestock species. *Theriogenology.* 2020;158:105–111. doi: [10.1016/j.theriogenology.2020.06.042](https://doi.org/10.1016/j.theriogenology.2020.06.042)
53. van der Weijden VA, Bulut-Karslioglu A. Molecular regulation of paused pluripotency in early mammalian embryos and stem cells. *Front Cell devbiol.* 2021;9:708318. doi: [10.3389/fcell.2021.708318](https://doi.org/10.3389/fcell.2021.708318)
54. Minder JL, Winokur SB, Stephens J, et al. Oxytocin induces embryonic diapause. *Sci Adv.* 2025;11(10):eadt1763. doi: [10.1126/sciadv.adt1763](https://doi.org/10.1126/sciadv.adt1763)
55. Fu Z, Wang B, Wang S, et al. Integral proteomic analysis of blastocysts reveals key molecular machinery governing embryonic diapause and reactivation for implantation in mice. *Biol Reprod.* 2014;90(3):1–11. doi: [10.1095/biolreprod.113.115337](https://doi.org/10.1095/biolreprod.113.115337)
56. Hussein AM, Balachandar N, Mathieu J, et al. Molecular regulators of embryonic diapause and cancer diapause-like state. *Cells.* 2022;11(19):2929. doi: [10.3390/cells11192929](https://doi.org/10.3390/cells11192929)
57. Hiratsuka D, Aikawa S, Hirota Y, et al. Dna methylation and histone modification are the possible regulators of preimplantation blastocyst activation in mice. *Reprod Sci.* 2023;30(2):494–525. doi: [10.1007/s43032-022-00988-x](https://doi.org/10.1007/s43032-022-00988-x)
58. Collignon E, Cho B, Furlan G, et al. m6A RNA methylation orchestrates transcriptional dormancy during paused pluripotency. *Nat cellbiol.* 2023;25(9):1279–1289. doi: [10.1038/s41556-023-01212-x](https://doi.org/10.1038/s41556-023-01212-x)
- **First study providing mechanistic insights on diapause that include global mRNA destabilization and suppression of global nascent transcription.**
59. Liu W-M, Pang RT, Cheong AW, et al. Involvement of microRNA lethal-7a in the regulation of embryo implantation in mice. *PLOS ONE.* 2012;7(5):e37039.

60. Liu W, Cheng R, Niu Z, et al. Let-7 derived from endometrial extracellular vesicles is an important inducer of embryonic diapause in mice. *Sci Adv.* 2020;6(37):eaaz7070. doi: [10.1126/sciadv.aaz7070](https://doi.org/10.1126/sciadv.aaz7070)
61. Hussein AM, Wang Y, Mathieu J, et al. Metabolic control over mTOR-dependent diapause-like state. *Dev Cell.* 2020;52(2):236--250.e7. doi: [10.1016/j.devcel.2019.12.018](https://doi.org/10.1016/j.devcel.2019.12.018)
62. Wang Y, Hussein AM, Somasundaram L, et al. MicroRNAs regulating human and mouse naïve pluripotency. *Int J molsci.* 2019;20(23):5864. doi: [10.3390/ijms20235864](https://doi.org/10.3390/ijms20235864)
63. Karami N, Taei A, Eftekhari-Yazdi P, et al. Signaling pathway regulators in preimplantation embryos. *J Molhistol.* 2024;56(1):57. doi: [10.1007/s10735-024-10338-7](https://doi.org/10.1007/s10735-024-10338-7)
64. Bulut-Karslioglu A, Biechele S, Jin H, et al. Inhibition of mTOR induces a paused pluripotent state. *Nature.* 2016;540(7631):119–123. doi: [10.1038/nature20578](https://doi.org/10.1038/nature20578)
65. Ptak GE, Modlinski JA, Loi P. Embryonic diapause in humans: time to consider? *Reprod Biolendocrinol.* 2013;11(1):92. doi: [10.1186/1477-7827-11-92](https://doi.org/10.1186/1477-7827-11-92)
66. Grinsted J, Avery B. A sporadic case of delayed implantation after in-vitro fertilization in the human? *Hum Reprod.* 1996;11(3):651–654. doi: [10.1093/HUMREP/11.3.651](https://doi.org/10.1093/HUMREP/11.3.651)
67. Barnea E, Absalon-Medina V. Embryo diapause as replicated by assisted reproductive technologies (ART): modern applications of an ancient species survival mechanism. *GREM.* 2021;2:189–196.
68. Iyer DP, Khoei HH, van der Weijden VA, et al. mTOR activity paces human blastocyst stage developmental progression. *Cell.* 2024;187(23):6566–6583.e22. doi: [10.1016/j.cell.2024.08.048](https://doi.org/10.1016/j.cell.2024.08.048)
- **In vitro study on the role of mTOR signaling pathway in inducing a diapause-like state in hPSCs and blastoids, with implications for reproductive therapies.**
69. Desrochers LM, Bordeleau F, Reinhart-King CA, et al. Microvesicles provide a mechanism for intercellular communication by embryonic stem cells during embryo implantation. *Nat Commun.* 2016;7(1):11958. doi: [10.1038/ncomms11958](https://doi.org/10.1038/ncomms11958)
70. Capalbo A, Treff N, Cimadomo D, et al. Abnormally fertilized oocytes can result in healthy live births: improved genetic technologies for preimplantation genetic testing can be used to rescue viable embryos in in vitro fertilization cycles. *Fertil Steril.* 2017;108(6):1007–1015.e3.
71. Scarpellini F, Klinger FG, Rossi G, et al. Immunohistochemical study on the expression of G-CSF, G-CSFR, VEGF, VEGFR-1, Foxp3 in first trimester trophoblast of recurrent pregnancy loss in pregnancies treated with G-CSF and controls. *Int J Mol Sci.* 2020;21(1):285.
72. Sbracia M, McKinnon B, Scarpellini F, et al. Preimplantation factor in endometriosis: a potential role in inducing immune privilege for ectopic endometrium. *PLOS ONE.* 2017;12(9):e0184399. doi: [10.1371/journal.pone.0184399](https://doi.org/10.1371/journal.pone.0184399)
73. Ochoa-Bernal MA, Fazleabas AT. Physiologic events of embryo implantation and decidualization in human and non-human primates. *Int J molsci.* 2020;21(6):1973. doi: [10.3390/ijms21061973](https://doi.org/10.3390/ijms21061973)
74. Zhang C, Li Y, Wu Y, et al. Interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration. *J Biol Chem.* 2013;288(3):1489–1499. doi: [10.1074/jbc.M112.419788](https://doi.org/10.1074/jbc.M112.419788)
75. Thaxton JE, Sharma S. Interleukin-10: a multi-faceted agent of pregnancy. *Am J reprodimmunol.* 2010;63(6):482–491.
76. Blois SM, Freitag N, Tirado-Gonzalez I, et al. Nk cell-derived IL-10 is critical for DC-NK cell dialogue at the maternal-fetal interface. *SciRep.* 2017;7(1):2189. doi: [10.1038/s41598-017-02333-8](https://doi.org/10.1038/s41598-017-02333-8)
77. Sharma S, Godbole G, Modi D. Decidual control of trophoblast invasion. *Am J reprodimmunol.* 2016;75(3):341–350. doi: [10.1111/aji.12466](https://doi.org/10.1111/aji.12466)
78. Vilotic A, Nacka-Aleksic M, Pirkovic A, et al. Il-6 and il-8: an overview of their roles in healthy and pathological pregnancies. *Int J molsci.* 2022;23(23):14574. doi: [10.3390/ijms232314574](https://doi.org/10.3390/ijms232314574)
79. Li S, Wang L, Xing Z, et al. Expression level of TNF-alpha in decidual tissue and peripheral blood of patients with recurrent spontaneous abortion. *Cent Eur J Immunol.* 2017;42(2):156–160.
80. Ma C, Liu G, Liu W, et al. Cxcl1 stimulates decidual angiogenesis via the VEGF-A pathway during the first trimester of pregnancy. *Mol Cell Bio Chem.* 2021;476(8):2989–2998. doi: [10.1007/s11010-021-04137-x](https://doi.org/10.1007/s11010-021-04137-x)
81. Scarpellini F, Klinger FG, Rossi G, et al. Immunohistochemical study on the expression of G-CSF, G-CSFR, VEGF, VEGFR-1, Foxp3 in first trimester trophoblast of recurrent pregnancy loss in pregnancies treated with G-CSF and controls. *Int J Mol Sci.* 2019;21(1):285. doi: [10.3390/ijms21010285](https://doi.org/10.3390/ijms21010285)
82. Scarpellini F, Sbracia M. Modification of peripheral Treg and CD56 (bright)NK levels in RIF women after egg donation, treated with GM-CSF or placebo. *J Reprodimmunol.* 2023;158:103983.
83. Mori M, Bogdan A, Balassa T, et al. The decidual-the maternal bed embracing the embryo-maintains the pregnancy. *SeminImmunopathol.* 2016;38(6):635–649. doi: [10.1007/s00281-016-0574-0](https://doi.org/10.1007/s00281-016-0574-0)
84. Shimada H, Powell TL, Jansson T. Regulation of placental amino acid transport in health and disease. *Acta Physiol (Oxf).* 2024;240(7):e14157. doi: [10.1111/apha.14157](https://doi.org/10.1111/apha.14157)
85. Muter J, Kong CS, Brosens JJ. The role of decidual subpopulations in implantation, menstruation and miscarriage. *Front Reprod Health.* 2021;3:804921. doi: [10.3389/frph.2021.804921](https://doi.org/10.3389/frph.2021.804921)
86. Vinketova K, Mourdjeva M, Oreshkova T. Human decidual stromal cells as a component of the implantation niche and a modulator of maternal immunity. *J Pregnancy.* 2016;2016:8689436.
87. Flores-Espinosa P, Mendez I, Irlas C, et al. Immunomodulatory role of decidual prolactin on the human fetal membranes and placenta. *Front Immunol.* 2023;14:1212736. doi: [10.3389/fimmu.2023.1212736](https://doi.org/10.3389/fimmu.2023.1212736)
88. Wang Y, Lv Y, Gao S, et al. MicroRNA profiles in spontaneous decidualized menstrual endometrium and early pregnancy decidua with successfully implanted embryos. *PLOS ONE.* 2016;11(1):e0143116. doi: [10.1371/journal.pone.0143116](https://doi.org/10.1371/journal.pone.0143116)
89. Li L, Feng T, Zhou W, et al. MiRnas in decidual NK cells: regulators worthy of attention during pregnancy. *Reprod Biolendocrinol.* 2021;19(1):150. doi: [10.1186/s12958-021-00812-2](https://doi.org/10.1186/s12958-021-00812-2)
90. Li R, Wen YX, Geng YQ, et al. miR-21a inhibits decidual cell apoptosis by targeting Pdc4. *Genes Dis.* 2021;8(2):171–180. doi: [10.1016/j.gendis.2019.09.013](https://doi.org/10.1016/j.gendis.2019.09.013)
91. Zhu Y, Lu H, Huo Z, et al. MicroRNA-16 inhibits fetomaternal angiogenesis and causes recurrent spontaneous abortion by targeting vascular endothelial growth factor. *Sci Rep.* 2016;6(1):35536. doi: [10.1038/srep35536](https://doi.org/10.1038/srep35536)
92. Su Y, Long J, Diao J, et al. Dysregulation of the circ-Hdac4/miR-30c/RBPJ axis in decidua impairs placental function in preeclampsia. *Cell BiolToxicol.* 2025;41(1):68. doi: [10.1007/s10565-025-10016-8](https://doi.org/10.1007/s10565-025-10016-8)
93. Vento-Tormo R, Efremova M, Botting RA, et al. Single-cell reconstruction of the early maternal-fetal interface in humans. *Nature.* 2018;563(7731):347–353. doi: [10.1038/s41586-018-0698-6](https://doi.org/10.1038/s41586-018-0698-6)
94. Robertson SA, Care AS, Moldenhauer LM. Regulatory T cells in embryo implantation and the immune response to pregnancy. *J Clininvest.* 2018;128(10):4224–4235. doi: [10.1172/JCI122182](https://doi.org/10.1172/JCI122182)
95. Ng YH, Rome S, Jalabert A, et al. Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation. *PLOS ONE.* 2013;8(3):e58502. doi: [10.1371/journal.pone.0058502](https://doi.org/10.1371/journal.pone.0058502)
96. Suh M-R, Lee Y, Kim JY, et al. Human embryonic stem cells express a unique set of microRNAs. *Dev Biol.* 2004;270(2):488–498. doi: [10.1016/j.ydbio.2004.02.019](https://doi.org/10.1016/j.ydbio.2004.02.019)
97. Gross N, Kropp J, Khatib H. MicroRNA signaling in embryo development. *Biol (Basel).* 2017;6(3):34. doi: [10.3390/biology6030034](https://doi.org/10.3390/biology6030034)
98. Sonnen KF, Janda CY. Signalling dynamics in embryonic development. *Bio Chem J.* 2021;478(23):4045–4070. doi: [10.1042/BCJ20210043](https://doi.org/10.1042/BCJ20210043)
99. Saadeldin IM, Pavani KC, Gnagnarelli J, et al. Unlocking a decade of research on embryo-derived extracellular vesicles: discoveries made and paths ahead. *STEM Cell revrep.* 2025;21(3):698–708. doi: [10.1007/s12015-025-10844-5](https://doi.org/10.1007/s12015-025-10844-5)

100. Li X, Zhang W, Fu J, et al. MicroRNA-451 is downregulated in the follicular fluid of women with endometriosis and influences mouse and human embryonic potential. *Reprod biolendocrinol.* 2019;17(1):96. doi: [10.1186/s12958-019-0538-z](https://doi.org/10.1186/s12958-019-0538-z)
101. Liu J, Xiao Q, Xiao J, et al. Wnt/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities. *Signal Transduct targetther.* 2022;7(1):3.
102. Martinez RM, Liang L, Racowsky C, et al. Extracellular microRNAs profile in human follicular fluid and IVF outcomes. *Sci Rep.* 2018;8(1):17036. doi: [10.1038/s41598-018-35379-3](https://doi.org/10.1038/s41598-018-35379-3)
103. Yao J, Li M, Lin L, et al. Pten expression in human cumulus cells is associated with embryo development competence. *Zygote.* 2022;30(5):611–618. doi: [10.1017/S096719942200003X](https://doi.org/10.1017/S096719942200003X)
104. Jian O, MengXia N, Shiyu X, et al. Mir-145 is upregulated in the retarded preimplantation embryos and modulates cholesterol levels in mice preimplantation embryos through targeting Abca1. *Reprod biolendocrinol.* 2022;20(1):168. doi: [10.1186/s12958-022-01044-8](https://doi.org/10.1186/s12958-022-01044-8)
105. Wang F, Yan J. MicroRNA-454 is involved in regulating trophoblast cell proliferation, apoptosis, and invasion in preeclampsia by modulating the expression of ephrin receptor B4. *Biomed Pharmacother.* 2018;107:746–753. doi: [10.1016/j.biopha.2018.08.055](https://doi.org/10.1016/j.biopha.2018.08.055)
106. Battaglia R, Palini S, Vento ME, et al. Identification of extracellular vesicles and characterization of miRNA expression profiles in human blastocoel fluid. *Sci Rep.* 2019;9(1):84. doi: [10.1038/s41598-018-36452-7](https://doi.org/10.1038/s41598-018-36452-7)
- **First study demonstrating the presence of microRNAs and extracellular vesicles in human blastocoel fluid.**
107. Moradi S, Sharifi-Zarchi A, Ahmadi A, et al. Small RNA sequencing reveals Dlk1-Dio3 locus-embedded microRNAs as major drivers of ground-state pluripotency. *STEM Cell Rep.* 2017;9(6):2081–2096. doi: [10.1016/j.stemcr.2017.10.009](https://doi.org/10.1016/j.stemcr.2017.10.009)
108. Fazeli A, Godakumara K. The evolving roles of extracellular vesicles in embryo-maternal communication. *Commun Biol.* 2024;7(1):754. doi: [10.1038/s42003-024-06442-9](https://doi.org/10.1038/s42003-024-06442-9)
109. Yap XL, Chen JA. Elucidation of how the mir-23–27–24 cluster regulates development and aging. *Exp Mol Med.* 2024;56(6):1263–1271. doi: [10.1038/s12276-024-01266-3](https://doi.org/10.1038/s12276-024-01266-3)
110. Xia W, Xie W. Rebooting the epigenomes during mammalian early embryogenesis. *STEM Cell Rep.* 2020;15(6):1158–1175. doi: [10.1016/j.stemcr.2020.09.005](https://doi.org/10.1016/j.stemcr.2020.09.005)
111. Zuccarello D, Sorrentino U, Brasson V, et al. Epigenetics of pregnancy: looking beyond the DNA code. *J Assist Reprod Genet.* 2022;39(4):801–816. doi: [10.1007/s10815-022-02451-x](https://doi.org/10.1007/s10815-022-02451-x)
112. Huang CC, Hsueh YW, Chang CW, et al. Establishment of the fetal-maternal interface: developmental events in human implantation and placentation. *Front Cell devbiol.* 2023;11:1200330. doi: [10.3389/fcell.2023.1200330](https://doi.org/10.3389/fcell.2023.1200330)
113. Enciso M, Aizpurua J, Rodriguez-Estrada B, et al. The precise determination of the window of implantation significantly improves ART outcomes. *Sci Rep.* 2021;11(1):13420. doi: [10.1038/s41598-021-92955-w](https://doi.org/10.1038/s41598-021-92955-w)
114. Salmasi S, Heidar MS, Khaksary Mahabady M, et al. MicroRNAs, endometrial receptivity and molecular pathways. *Reprod biolendocrinol.* 2024;22(1):139. doi: [10.1186/s12958-024-01304-9](https://doi.org/10.1186/s12958-024-01304-9)
115. Massimiani M, Lacconi V, La Civita F, et al. Molecular signaling regulating endometrium-blastocyst crosstalk. *Int J Mol Sci.* 2019;21(1):23. doi: [10.3390/ijms21010023](https://doi.org/10.3390/ijms21010023)
116. Wu HM, Chen LH, Hsu LT, et al. Immune tolerance of embryo implantation and pregnancy: the role of human decidual stromal cell- and embryonic-derived extracellular vesicles. *Int J Mol Sci.* 2022;23(21):13382. doi: [10.3390/ijms232113382](https://doi.org/10.3390/ijms232113382)
117. Andrawus M, Sharvit L, Atzmon G. Epigenetics and pregnancy: conditional snapshot or rolling event. *Int J Mol Sci.* 2022;23(20):12698. doi: [10.3390/ijms232012698](https://doi.org/10.3390/ijms232012698)
118. Retis-Resendiz AM, Gonzalez-Garcia IN, Leon-Juarez M, et al. The role of epigenetic mechanisms in the regulation of gene expression in the cyclical endometrium. *Clin Epigenet.* 2021;13(1):116. doi: [10.1186/s13148-021-01103-8](https://doi.org/10.1186/s13148-021-01103-8)
119. Jin M, Ji J, Chen X, et al. The emerging role of TET enzymes in the immune microenvironment at the maternal-fetal interface during decidualization and early pregnancy. *Front Immunol.* 2022;13:1066599.
120. Pirlog LM, Patrascanu AA, Ona MD, et al. Hoxa10 and Hoxa11 in human endometrial benign disorders: unraveling molecular pathways and their impact on reproduction. *Bio Molecules.* 2025;15(4):563. doi: [10.3390/biom15040563](https://doi.org/10.3390/biom15040563)
121. Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. *Sig Transduct Targetther.* 2021;6(1):74. doi: [10.1038/s41392-020-00450-x](https://doi.org/10.1038/s41392-020-00450-x)
122. Hu X, Li J, Ding C, et al. Mettl3/eed/ythdc1 regulatory axis controls endometrial receptivity and function. *Commun Biol.* 2025;8(1):215. doi: [10.1038/s42003-025-07667-y](https://doi.org/10.1038/s42003-025-07667-y)
123. Pilala KM, Panoutsopoulou K, Papadimitriou MA, et al. Exploring the methyl-verse: dynamic interplay of epigenome and m6A epitranscriptome. *Mol Ther.* 2025;33(2):447–464. doi: [10.1016/j.ymthe.2024.12.003](https://doi.org/10.1016/j.ymthe.2024.12.003)
124. Cui X, Li H, Huang X, et al. N(6)-methyladenosine modification on the function of female reproductive development and related diseases. *Immun Inflamm Dis.* 2024;12(12):e70089.
125. Yu SL, Kim TH, Han YH, et al. Transcriptomic analysis and competing endogenous RNA network in the human endometrium between proliferative and mid-secretory phases. *Exp Thermed.* 2021;21(6):660. doi: [10.3892/etm.2021.10092](https://doi.org/10.3892/etm.2021.10092)
126. Hasanabadi HE, Govahi A, Chaichian S, et al. Lncrnas in the regulation of endometrial receptivity for embryo implantation. *JBRA assistreprod.* 2024;28(3):503–510. doi: [10.5935/1518-0557.20240038](https://doi.org/10.5935/1518-0557.20240038)
127. Timofeeva AV, Fedorov IS, Shamina MA, et al. Clinical relevance of secreted small noncoding RNAs in an embryo implantation potential prediction at morula and blastocyst development stages. *Life (Basel).* 2021;11(12):1328. doi: [10.3390/life11121328](https://doi.org/10.3390/life11121328)
128. Rosa A, Brivanlou AH. Role of microRNAs in zygotic genome activation: modulation of mRNA during embryogenesis. *Methods Mol Biol.* 2017;1605:31–43.
129. Atkinson SA, Fraher L, Gundberg CM, et al. Mineral homeostasis and bone mass in children treated for acute lymphoblastic leukemia. *J Pediatr.* 1989;114(5):793–800. doi: [10.1016/S0022-3476\(89\)80138-6](https://doi.org/10.1016/S0022-3476(89)80138-6)
130. Liang J, Cao D, Zhang X, et al. MiR-192-5p suppresses uterine receptivity formation through impeding epithelial transformation during embryo implantation. *Theriogenology.* 2020;157:360–371. doi: [10.1016/j.theriogenology.2020.08.009](https://doi.org/10.1016/j.theriogenology.2020.08.009)
131. Zhai J, Yao GD, Wang JY, et al. Metformin regulates key microRNAs to improve endometrial receptivity through increasing implantation marker gene expression in patients with PCOS undergoing IVF/ICSI. *Reprod Sci.* 2019;26(11):1439–1448. doi: [10.1177/1933719118820466](https://doi.org/10.1177/1933719118820466)
132. Voros C, Varthaliti A, Athanasiou D, et al. MicroRNA signatures in endometrial receptivity-unlocking their role in embryo implantation and IVF success: a systematic review. *Bio Medicines.* 2025;13(5):1189. doi: [10.3390/biomedicines13051189](https://doi.org/10.3390/biomedicines13051189)
133. Akbar R, Ullah K, Rahman TU, et al. MiR-183-5p regulates uterine receptivity and enhances embryo implantation. *J Molendocrinol.* 2020;64(1):43–52. doi: [10.1530/JME-19-0184](https://doi.org/10.1530/JME-19-0184)
134. Li L, Liu L, Kou Z, et al. GnRH agonist treatment regulates IL-6 and IL-11 expression in endometrial stromal cells for patients with HRT regimen in frozen embryo transfer cycles. *Reprod Biol.* 2022;22(2):100608. doi: [10.1016/j.repbio.2022.100608](https://doi.org/10.1016/j.repbio.2022.100608)
135. Soczewski E, Murrieta-Coxca JM, Miranda L, et al. miRNAs associated with endoplasmic reticulum stress and unfolded protein response during decidualization. *Reprod Biomed Online.* 2023;47(5):103289. doi: [10.1016/j.rbmo.2023.103289](https://doi.org/10.1016/j.rbmo.2023.103289)
136. Riyanti A, Febri RR, Zakirah SC, et al. Suppressing HOXA-10 gene expression by microRNA 135b during the window of implantation in infertile women. *J Reprod Infertil.* 2020;21(3):217–221.
137. Petracco R, Grechukhina O, Popkhadze S, et al. MicroRNA 135 regulates HOXA10 expression in endometriosis. *J Clin endocrinol-metab.* 2011;96(12):E1925–33. doi: [10.1210/jc.2011-1231](https://doi.org/10.1210/jc.2011-1231)

138. Kang YJ, Lees M, Matthews LC, et al. Mir-145 suppresses embryo-epithelial juxtacrine communication at implantation by modulating maternal IGF1R. *J Cell Sci.* 2015;128(4):804–814. doi: [10.1242/jcs.164004](https://doi.org/10.1242/jcs.164004)
139. Di Pietro C, Caruso S, Battaglia R, et al. MiR-27a-3p and miR-124-3p, upregulated in endometrium and serum from women affected by chronic endometritis, are new potential molecular markers of endometrial receptivity. *Am J Reprod Immunol.* 2018;80(3):e12858. doi: [10.1111/aji.12858](https://doi.org/10.1111/aji.12858)
140. Altmae S, Koel M, Vosa U, et al. Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. *Sci Rep.* 2017;7(1):10077. doi: [10.1038/s41598-017-10098-3](https://doi.org/10.1038/s41598-017-10098-3)
141. Salmasi S, Sharifi M, Rashidi B. Evaluating the effect of ovarian stimulation and exogenous progesterone on CD31-positive cell density, VEGF protein, and miR-17-5p expression of endometrium immediately before implantation. *Biomed Pharmacother.* 2021;133:110922. doi: [10.1016/j.biopha.2020.110922](https://doi.org/10.1016/j.biopha.2020.110922)
142. Salmasi S, Sharifi M, Rashidi B. Ovarian stimulation and exogenous progesterone affect the endometrial miR-16-5p, VEGF protein expression, and angiogenesis. *Microvasc Res.* 2021;133:104074. doi: [10.1016/j.mvr.2020.104074](https://doi.org/10.1016/j.mvr.2020.104074)
143. Liu YN, Li KY, Wei H, et al. Rna binding protein HuR regulated by OIP5-AS1 may be involved in maternal transcript degradation during the human maternal-to-zygotic transition. *BMC Genomics.* 2025;26(1):600. doi: [10.1186/s12864-025-11807-3](https://doi.org/10.1186/s12864-025-11807-3)
144. Wang H, Ni C, Xiao W, et al. Role of lncRNA FTX in invasion, metastasis, and epithelial-mesenchymal transition of endometrial stromal cells caused by endometriosis by regulating the PI3K/Akt signaling pathway. *Ann Transl Med.* 2020;8(22):1504. doi: [10.21037/atm-20-6810](https://doi.org/10.21037/atm-20-6810)
145. Liang XH, Deng WB, Liu YF, et al. Non-coding RNA LINC00473 mediates decidualization of human endometrial stromal cells in response to cAMP signaling. *Sci Rep.* 2016;6(1):22744. doi: [10.1038/srep22744](https://doi.org/10.1038/srep22744)
- **First report demonstrating the presence of lincRNA during human decidualization.**
146. Qiu JJ, Ren ZR, Yan JB. Identification and functional analysis of long non-coding RNAs in human and mouse early embryos based on single-cell transcriptome data. *Oncotarget.* 2016;7(38):61215–61228. doi: [10.18632/oncotarget.11304](https://doi.org/10.18632/oncotarget.11304)
147. Liu LP, Gong YB. Lncrna-tcl6 promotes early abortion and inhibits placenta implantation via the EGFR pathway. *Eur Rev Med PharmacolSci.* 2018;22(21):7105–7112. doi: [10.26355/eurrev_201811_16242](https://doi.org/10.26355/eurrev_201811_16242)
148. Jia Y, Wang W, Jiang J, et al. LncRNA STAT3-AS regulates endometrial receptivity via the STAT3 signaling pathway. *Theriogenology.* 2024;216:118–126. doi: [10.1016/j.theriogenology.2023.12.032](https://doi.org/10.1016/j.theriogenology.2023.12.032)
149. Wang Y, Hu S, Yao G, et al. A novel molecule in human cyclic endometrium: lncRNA TUNAR is involved in embryo implantation. *Front Physiol.* 2020;11:587448. doi: [10.3389/fphys.2020.587448](https://doi.org/10.3389/fphys.2020.587448)
150. Wang X, Ramat A, Simonelig M, et al. Emerging roles and functional mechanisms of PIWI-interacting RNAs. *Nat Rev Mol Cell Biol.* 2023;24(2):123–141. doi: [10.1038/s41580-022-00528-0](https://doi.org/10.1038/s41580-022-00528-0)
151. Lv X, Zhang H, Wu L. Advances in PIWI-piRNA function in female reproduction in mammals. *Acta Biochim Biophys Sin (Shanghai).* 2024;57(1):148–156.
152. Wu PH, Zamore PD. Defining the functions of PIWI-interacting RNAs. *Nat Rev Mol Cell Biol.* 2021;22(4):239–240. doi: [10.1038/s41580-021-00336-y](https://doi.org/10.1038/s41580-021-00336-y)
153. Ma Y, Hou B, Zong J, et al. Potential molecular mechanisms and clinical implications of piRNAs in preeclampsia: a review. *Reprod Biol Endocrinol.* 2024;22(1):73. doi: [10.1186/s12958-024-01247-1](https://doi.org/10.1186/s12958-024-01247-1)
154. Lin J, Zhou Y, Gu W. Novel piRNA regulates PIWIL1 to modulate the behavior of placental trophoblast cells and participates in preeclampsia. *Oxid Med Cell Longev.* 2022;2022(1):7856290. doi: [10.1155/2022/7856290](https://doi.org/10.1155/2022/7856290)
155. Fradin D, Tost J, Busato F, et al. Dna methylation dynamics during pregnancy. *Front Cell Dev Biol.* 2023;11:1185311. doi: [10.3389/fcell.2023.1185311](https://doi.org/10.3389/fcell.2023.1185311)
156. Tekola-Ayele F, Zeng X, Ouidir M, et al. DNA methylation loci in placenta associated with birthweight and expression of genes relevant for early development and adult diseases. *Clin Epigenet.* 2020;12(1):78. doi: [10.1186/s13148-020-00873-x](https://doi.org/10.1186/s13148-020-00873-x)
157. Ma X, Chen X, Mu X, et al. Epigenetics of maternal-fetal interface immune microenvironment and placental related pregnancy complications. *Front Immunol.* 2025;16:1549839. doi: [10.3389/fimmu.2025.1549839](https://doi.org/10.3389/fimmu.2025.1549839)
158. Chen Y, Ye Z, Lin M, et al. Deciphering the epigenetic landscape: placental development and its role in pregnancy outcomes. *STEM Cell Rev Rep.* 2024;20(4):996–1014. doi: [10.1007/s12015-024-10699-2](https://doi.org/10.1007/s12015-024-10699-2)
159. Coppede F, Franzago M, Giardina E, et al. A perspective on diet, epigenetics and complex diseases: where is the field headed next? *Epigenomics.* 2022;14(20):1281–1304. doi: [10.2217/epi-2022-0239](https://doi.org/10.2217/epi-2022-0239)
160. Mirzakhani H. From womb to wellness: early environmental exposures, cord blood DNA methylation and disease origins. *Epigenomics.* 2024;16(17):1175–1183. doi: [10.1080/17501911.2024.2390823](https://doi.org/10.1080/17501911.2024.2390823)
161. Salvatori F, D'Aversa E, Serino ML, et al. Mirnas epigenetic tuning of wall remodeling in the early phase after myocardial infarction: a novel epidrug approach. *Int J Mol Sci.* 2023;24(17):13268. doi: [10.3390/ijms241713268](https://doi.org/10.3390/ijms241713268)
162. Atzemian N, Mohammed S, Di Venanzio L, et al. Cardiometabolic disease management: influences from epigenetics. *Epigenomics.* 2025;17(7):463–474. doi: [10.1080/17501911.2025.2489921](https://doi.org/10.1080/17501911.2025.2489921)
163. Ek WE, Rask-Andersen M, Johansson A. The role of DNA methylation in the pathogenesis of disease: what can epigenome-wide association studies tell? *Epigenomics.* 2016;8(1):5–7. doi: [10.2217/epi.15.99](https://doi.org/10.2217/epi.15.99)
164. Karalija E, Ibragic S, Dahija S, et al. Transgenerational memory of phenotypic traits in plants: epigenetic regulation of growth, hormonal balance, and stress adaptation. *Curr Issues Mol Biol.* 2025;47(6):404. doi: [10.3390/cimb47060404](https://doi.org/10.3390/cimb47060404)
165. Ibragic S, Dahija S, Karalija E. The good, the bad, and the epigenetic: stress-induced metabolite regulation and transgenerational effects. *Epigenomes.* 2025;9(2):10. doi: [10.3390/epigenomes9020010](https://doi.org/10.3390/epigenomes9020010)
166. Cheong JJ. Transgenerational transmission of epigenetic marks during reproduction in Arabidopsis. *Yale J Biol Med.* 2025;98(2):245–251. doi: [10.59249/EWLZ5537](https://doi.org/10.59249/EWLZ5537)
167. Frias-Lasserre D, Villagra CA. The importance of ncRNAs as epigenetic mechanisms in phenotypic variation and organic evolution. *Front Microbiol.* 2017;8:2483. doi: [10.3389/fmicb.2017.02483](https://doi.org/10.3389/fmicb.2017.02483)
168. Banushi B, Collava J, Milroy H. Epigenetic echoes: bridging nature, nurture, and healing across generations. *Int J Mol Sci.* 2025;26(7):3075. doi: [10.3390/ijms26073075](https://doi.org/10.3390/ijms26073075)
169. Belton C, Kelsey G. Mediators of maternal intergenerational epigenetic inheritance in mammals. *Epigenomics.* 2025;17(12):1–9. doi: [10.1080/17501911.2025.2525749](https://doi.org/10.1080/17501911.2025.2525749)
170. Bohacek J, Mansuy IM. Molecular insights into transgenerational non-genetic inheritance of acquired behaviours. *Nat Rev Genet.* 2015;16(11):641–652. doi: [10.1038/nrg3964](https://doi.org/10.1038/nrg3964)
171. Jawaid A, Jehle KL, Mansuy IM. Impact of parental exposure on offspring health in humans. *Trends Genet.* 2021;37(4):373–388. doi: [10.1016/j.tig.2020.10.006](https://doi.org/10.1016/j.tig.2020.10.006)
- **Comprehensive review on the contribution of epigenetic factors to heredity in humans.**
172. Ho DH. Transgenerational epigenetics: the role of maternal effects in cardiovascular development. *Integr Comp Biol.* 2014;54(1):43–51. doi: [10.1093/icb/icu031](https://doi.org/10.1093/icb/icu031)
173. Burton NO, Greer EL. Multigenerational epigenetic inheritance: transmitting information across generations. *Semin Cell Dev Biol.* 2022;127:121–132. doi: [10.1016/j.semcd.2021.08.006](https://doi.org/10.1016/j.semcd.2021.08.006)
174. Kaeffer B. Human breast milk miRNAs: their diversity and potential for preventive strategies in nutritional therapy. *Int J Mol Sci.* 2023;24(22):16106. doi: [10.3390/ijms242216106](https://doi.org/10.3390/ijms242216106)
175. Gaylord A, Holzhausen EA, Chalifour B, et al. tRNA-derived RNAs in human milk extracellular vesicles and associations with breastfeeding variables and maternal diet. *Epigenomics.* 2024;16(23–24):1429–1441. doi: [10.1080/17501911.2024.2430943](https://doi.org/10.1080/17501911.2024.2430943)

176. Hjort L, Rushiti F, Wang SJ, et al. Intergenerational effects of maternal post-traumatic stress disorder on offspring epigenetic patterns and cortisol levels. *Epigenomics*. 2021;13(12):967–980. doi: 10.2217/epi-2021-0015
177. Duncan EM, Allis CD. Errors in erasure: links between histone lysine methylation removal and disease. *Prog drugres*. 2011;67:69–90.
178. Nilsson EE, Sadler-Riggelman I, Skinner MK. Environmentally induced epigenetic transgenerational inheritance of disease. *Environ Epigenet*. 2018;4(2):dvy016. doi: 10.1093/eep/dvy016
179. Khatib H, Townsend J, Konkel MA, et al. Calling the question: what is mammalian transgenerational epigenetic inheritance? *Epigenetics*. 2024;19(1):2333586. doi: 10.1080/15592294.2024.2333586
- **Transgenerational epigenetic inheritance has been widely documented in plants, worms, and flies, its existence in mammals remains controversial. This paper emphasizes the great confusion in this field calling for the imperative need for a wide scientific consensus and gives important basic statements.**
180. Chen Q, Yan W, Duan E. Epigenetic inheritance of acquired traits through sperm RNAs and sperm RNA modifications. *Nat Rev Genet*. 2016;17(12):733–743. doi: 10.1038/nrg.2016.106
181. Naveed M, Shen Z, Bao J. Sperm-borne small non-coding RNAs: potential functions and mechanisms as epigenetic carriers. *Cell Biosci*. 2025;15(1):5. doi: 10.1186/s13578-025-01347-4
- **This review investigates the mechanisms by which sperm-delivered snRNAs may acquire and transmit paternally acquired traits to offspring by modulating zygotic gene expression and influencing early embryonic development.**
182. Zheng X, Chen L, Li M, et al. Transgenerational variations in DNA methylation induced by drought stress in two rice varieties with distinguished difference to drought resistance. *PLOS ONE*. 2013;8(11):e80253. doi: 10.1371/journal.pone.0080253
183. Gapp K, Jawaid A, Sarkies P, et al. Implication of sperm RNAs in transgenerational inheritance of the effects of early trauma in mice. *Nat Neuro Sci*. 2014;17(5):667–669. doi: 10.1038/nn.3695
184. Yan W. Potential roles of noncoding RNAs in environmental epigenetic transgenerational inheritance. *Mol Cellendocrinol*. 2014;398(1–2):24–30. doi: 10.1016/j.mce.2014.09.008
185. Cuerda-Gil D, Slotkin RK. Non-canonical RNA-directed DNA methylation. *Nat Plants*. 2016;2(11):16163. doi: 10.1038/nplants.2016.163
186. Chow HT, Chakraborty T, Mosher RA. Rna-directed dna methylation and sexual reproduction: expanding beyond the seed. *Curr Opin Plant Biol*. 2020;54:11–17. doi: 10.1016/j.pbi.2019.11.006
187. Matzke MA, Mosher RA. Rna-directed dna methylation: an epigenetic pathway of increasing complexity. *Nat Rev Genet*. 2014;15(6):394–408. doi: 10.1038/nrg3683
188. Ben Maamar M, Sadler-Riggelman I, Beck D, et al. Alterations in sperm DNA methylation, non-coding RNA expression, and histone retention mediate vinclozolin-induced epigenetic transgenerational inheritance of disease. *Environ Epigenet*. 2018;4(2):dvy010. doi: 10.1093/eep/dvy010
189. Skinner MK, Ben Maamar M, Sadler-Riggelman I, et al. Alterations in sperm DNA methylation, non-coding RNA and histone retention associate with DDT-induced epigenetic transgenerational inheritance of disease. *Epigenet Chromatin*. 2018;11(1):8. doi: 10.1186/s13072-018-0178-0
190. Kouzarides T. Chromatin modifications and their function. *Cell*. 2007;128(4):693–705. doi: 10.1016/j.cell.2007.02.005
191. Jenkins TG, Carrell DT. The sperm epigenome and potential implications for the developing embryo. *Reproduction*. 2012;143(6):727–734. doi: 10.1530/REP-11-0450
192. Jenkins TG, Carrell DT. The paternal epigenome and embryogenesis: poisoning mechanisms for development. *Asian J Androl*. 2011;13(1):76–80. doi: 10.1038/aja.2010.61
193. Ben Maamar M, Sadler-Riggelman I, Beck D, et al. Epigenetic transgenerational inheritance of altered sperm histone retention sites. *Sci Rep*. 2018;8(1):5308. doi: 10.1038/s41598-018-23612-y
194. Wan QL, Meng X, Wang C, et al. Histone H3K4me3 modification is a transgenerational epigenetic signal for lipid metabolism in *Caenorhabditis elegans*. *Nat Commun*. 2022;13(1):768. doi: 10.1038/s41467-022-28469-4
195. Perez MF, Lehner B. Intergenerational and transgenerational epigenetic inheritance in animals. *Nat Cell Biol*. 2019;21(2):143–151. doi: 10.1038/s41556-018-0242-9
196. Klosin A, Casas E, Hidalgo-Carcedo C, et al. Transgenerational transmission of environmental information in *C. elegans*. *Science*. 2017;356(6335):320–323. doi: 10.1126/science.aah6412
197. Seong KH, Li D, Shimizu H, et al. Inheritance of stress-induced, ATF-2-dependent epigenetic change. *Cell*. 2011;145(7):1049–1061. doi: 10.1016/j.cell.2011.05.029
198. Jawaid A, Roszkowski M, Mansuy IM. Transgenerational epigenetics of traumatic stress. *Prog Mol Biol Transl Sci*. 2018;158:273–298.
199. van Otterdijk SD, Michels KB. Transgenerational epigenetic inheritance in mammals: how good is the evidence? *FASEBJ*. 2016;30(7):2457–2465. doi: 10.1096/fj.201500083
200. Klengel T, Dias BG, Ressler KJ. Models of intergenerational and transgenerational transmission of risk for psychopathology in mice. *Neuropsychopharmacology*. 2016;41(1):219–231. doi: 10.1038/npp.2015.249
201. Indrio F, Pietrobelli A, Dargenio VN, et al. The key 1000 life-changing days. *Global Pediatrics*. 2023;4:100049. doi: 10.1016/j.gped.2023.100049
202. Azoulay L, Bouvattier C, Christin-Maitre S. Impact of intra-uterine life on future health. *Ann Endocrinol (Paris)*. 2022;83(1):54–58. doi: 10.1016/j.ando.2021.11.010
203. Tisato V, Silva JA, Longo G, et al. Genetics and epigenetics of one-carbon metabolism pathway in autism spectrum disorder: a sex-specific brain epigenome? *Genes (Basel)*. 2021;12(5):782. doi: 10.3390/genes12050782
204. Tisato V, Muggeo P, Lupiano T, et al. Maternal haplotypes in DHFR promoter and MTHFR gene in tuning childhood acute lymphoblastic leukemia onset-latency: genetic/epigenetic mother/child dyad study (GEMCDS). *Genes (Basel)*. 2019;10(9):634. doi: 10.3390/genes10090634
205. Tisato V, Silva JA, Scarpellini F, et al. Epigenetic role of LINE-1 methylation and key genes in pregnancy maintenance. *Sci Rep*. 2024;14(1):3275. doi: 10.1038/s41598-024-53737-2
206. Gemmati D, Scarpellini F, Salvatori F, et al. Line-1 methylation sustains telomere length in pregnant women: effects on pregnancy failure. *Clin Epigenet*. 2025;17(1):130. doi: 10.1186/s13148-025-01937-6
207. Yehuda R, Lehrner A, Bierer LM. The public reception of putative epigenetic mechanisms in the transgenerational effects of trauma. *Environ Epigenet*. 2018;4(2). doi: 10.1093/eep/dvy018
208. Boscardin C, Manuella F, Mansuy IM. Paternal transmission of behavioural and metabolic traits induced by postnatal stress to the 5th generation in mice. *Environ Epigenet*. 2022;8(1). doi: 10.1093/eep/dvac024
209. van Steenwyk G, Roszkowski M, Manuella F, et al. Transgenerational inheritance of behavioural and metabolic effects of paternal exposure to traumatic stress in early postnatal life: evidence in the 4th generation. *Environ Epigenet*. 2018;4(2). doi: 10.1093/eep/dvy023
210. Naddaf M. Can trauma from violence be genetically inherited? Scientists debate Syria refugee study. *Nature*. 2025;640(8058):294–295. doi: 10.1038/d41586-025-00937-z
211. Mulligan CJ, Quinn EB, Hamadmad D, et al. Epigenetic signatures of intergenerational exposure to violence in three generations of Syrian refugees. *Sci Rep*. 2025;15(1):5945. doi: 10.1038/s41598-025-89818-z
212. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. *Mod Pathol*. 2013;26(4):465–484. doi: 10.1038/modpathol.2012.214
213. Tisato V, Castiglione A, Ciorba A, et al. Line-1 Global DNA methylation, iron homeostasis genes, sex and age in sudden sensorineural hearing loss (SSNHL). *Hum Genomics*. 2023;17(1):112. doi: 10.1186/s40246-023-00562-9
214. D'Aversa E, Salvatori F, Vaccarezza M, et al. CircRNAs as epigenetic regulators of integrity in blood-brain barrier architecture:

- mechanisms and therapeutic strategies in multiple sclerosis. *Cells*. 2024;13(16):1316. doi: [10.3390/cells13161316](https://doi.org/10.3390/cells13161316)
215. Dai W, Qiao X, Fang Y, et al. Epigenetics-targeted drugs: current paradigms and future challenges. *Sig Transduct targetther*. 2024;9(1):332. doi: [10.1038/s41392-024-02039-0](https://doi.org/10.1038/s41392-024-02039-0)
 216. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. *Clin cancerres*. 2005;11(10):3604–3608. doi: [10.1158/1078-0432.CCR-04-2135](https://doi.org/10.1158/1078-0432.CCR-04-2135)
 217. Samadieh Y, Favaedi R, Ramezani F, et al. Epigenetic dynamics of HOXA10 gene in infertile women with endometriosis. *Reprod Sci*. 2019;26(1):88–96. doi: [10.1177/1933719118766255](https://doi.org/10.1177/1933719118766255)
 218. Hassani HH, Lafta FM, Kh Al-Jumaily M. Epigenetics in male infertility. In: Wu W, editor. *Male reproductive anatomy*. Rijeka: Intech Open; 2021. doi: [10.5772/intechopen.99529](https://doi.org/10.5772/intechopen.99529)
 219. Adamczyk M, Wender-Ozegowska E, Kedzia M. Epigenetic factors in eutopic endometrium in women with endometriosis and infertility. *Int J Mol Sci*. 2022;23(7):3804. doi: [10.3390/ijms23073804](https://doi.org/10.3390/ijms23073804)
 220. Montalvo-Casimiro M, Gonzalez-Barrios R, Meraz-Rodriguez MA, et al. Epidrug repurposing: discovering new faces of old acquaintances in cancer therapy. *Front Oncol*. 2020;10:605386. doi: [10.3389/fonc.2020.605386](https://doi.org/10.3389/fonc.2020.605386)
 221. de Oliveira DT, Guerra-Sa R. Uncovering epigenetic landscape: a new path for biomarkers identification and drug development. *Mol Biol Rep*. 2020;47(11):9097–9122. doi: [10.1007/s11033-020-05916-3](https://doi.org/10.1007/s11033-020-05916-3)
 222. Laranjeira ABA, Hollingshead MG, Nguyen D, et al. Dna damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. *Sci Rep*. 2023;13(1):5964. doi: [10.1038/s41598-023-32509-4](https://doi.org/10.1038/s41598-023-32509-4)
 223. Gnyszka A, Jastrzebski Z, Flis S. Dna methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. *Anticancer Res*. 2013;33(8):2989–2996.
 224. Losson H, Schneckeburger M, Dicato M, et al. Natural compound histone deacetylase inhibitors (HDACi): synergy with inflammatory signaling pathway modulators and clinical applications in cancer. *Molecules*. 2016;21(11):1608. doi: [10.3390/molecules21111608](https://doi.org/10.3390/molecules21111608)
 225. Uchida H, Maruyama T, Arase T, et al. Histone acetylation in reproductive organs: significance of histone deacetylase inhibitors in gene transcription. *Reprod Med Biol*. 2005;4(2):115–122. doi: [10.1111/j.1447-0578.2005.00101.x](https://doi.org/10.1111/j.1447-0578.2005.00101.x)
 226. Sunita S, Singh PK, Onteru SK, et al. Histone deacetylase: a potential therapeutic target for ovarian dysfunction. *Front Bio Sci*. 2018;23(3):512–534.
 227. Psilopatis I, Vrettou K, Fleckenstein FN, et al. The impact of histone modifications in endometriosis highlights new therapeutic opportunities. *Cells*. 2023;12(9):1227. doi: [10.3390/cells12091227](https://doi.org/10.3390/cells12091227)
 228. Histone Methyltransferases (HMT). *Encyclopedia of genetics, genomics, proteomics and informatics*. Dordrecht: Springer Netherlands; 2008. p. 881–883.
 229. Colon-Caraballo M, Torres-Reveron A, Soto-Vargas JL, et al. Effects of histone methyltransferase inhibition in endometriosis. *Biol Reprod*. 2018;99(2):293–307.
 230. Ajayi AF, Oyovwi MO, Olatinwo G, et al. Unfolding the complexity of epigenetics in male reproductive aging: a review of therapeutic implications. *Mol Biol Rep*. 2024;51(1):881. doi: [10.1007/s11033-024-09823-9](https://doi.org/10.1007/s11033-024-09823-9)
 231. Kitamura A, Miyauchi N, Hamada H, et al. Epigenetic alterations in sperm associated with male infertility. *Congenit Anom (Kyoto)*. 2015;55(3):133–144. doi: [10.1111/cga.12113](https://doi.org/10.1111/cga.12113)
 232. Jiang T, Zhang C, Cao X, et al. Ezh1/2 plays critical roles in oocyte meiosis prophase I in mice. *Biol Res*. 2024;57(1):83. doi: [10.1186/s40659-024-00564-4](https://doi.org/10.1186/s40659-024-00564-4)
 233. Erdogan K, Sanlier NT, Sanlier N. Are epigenetic mechanisms and nutrition effective in male and female infertility? *J Nutr Sci*. 2023;12:e103. doi: [10.1017/jns.2023.62](https://doi.org/10.1017/jns.2023.62)
 234. Monasso GS, Hoang TT, Mancano G, et al. A meta-analysis of epigenome-wide association studies on pregnancy vitamin B12 concentrations and offspring DNA methylation. *Epigenetics*. 2023;18(1):2202835. doi: [10.1080/15592294.2023.2202835](https://doi.org/10.1080/15592294.2023.2202835)
 235. Mitchell LE, Adzick NS, Melchionne J, et al. Spina bifida. *Lancet*. 2004;364(9448):1885–1895. doi: [10.1016/S0140-6736\(04\)17445-X](https://doi.org/10.1016/S0140-6736(04)17445-X)
 236. Menezo Y, Elder K, Clement A, et al. Folic acid, folinic acid, 5 methyl tetrahydrofolate supplementation for mutations that affect epigenesis through the folate and one-carbon cycles. *Biomolecules*. 2022;12(2):197. doi: [10.3390/biom12020197](https://doi.org/10.3390/biom12020197)
 237. Mani S, Ghosh J, Coutifaris C, et al. Epigenetic changes and assisted reproductive technologies. *Epigenetics*. 2020;15(1–2):12–25. doi: [10.1080/15592294.2019.1646572](https://doi.org/10.1080/15592294.2019.1646572)
 238. La Rovere M, Franzago M, Stupia L. Epigenetics and neurological disorders in ART. *Int J Mol Sci*. 2019;20(17):4169. doi: [10.3390/ijms20174169](https://doi.org/10.3390/ijms20174169)
 239. Saucedo-Cuevas L, Ivanova E, Herta AC, et al. Genome-wide assessment of DNA methylation alterations induced by superovulation, sexual immaturity and in vitro follicle growth in mouse blastocysts. *Clin Epigenet*. 2023;15(1):9. doi: [10.1186/s13148-023-01421-z](https://doi.org/10.1186/s13148-023-01421-z)
 240. Robles V, Valcarce DG, Riesco MF. Non-coding RNA regulation in reproduction: their potential use as biomarkers. *Noncoding RNA Res*. 2019;4(2):54–62. doi: [10.1016/j.ncrna.2019.04.001](https://doi.org/10.1016/j.ncrna.2019.04.001)
 241. Thompson RP, Beck D, Nilsson E, et al. Examination of generational impacts of adolescent chemotherapy: ifosfamide and potential for epigenetic transgenerational inheritance. *iScience*. 2022;25(12):105570. doi: [10.1016/j.isci.2022.105570](https://doi.org/10.1016/j.isci.2022.105570)
 242. Delessard M, Saulnier J, Rives A, et al. Exposure to chemotherapy during childhood or adulthood and consequences on spermatogenesis and male fertility. *Int J Mol Sci*. 2020;21(4):1454. doi: [10.3390/ijms21041454](https://doi.org/10.3390/ijms21041454)
 243. Tremblay A, Beaud H, Delbes G. Transgenerational impact of chemotherapy: would the father exposure impact the health of future progeny? *Gynecol Obstet Fertil Senol*. 2017;45(11):609–618.
 244. Peluso G, Tisato V, Singh AV, et al. Semen cryopreservation to expand male fertility in cancer patients: intracoe evaluation of semen quality. *J Pers Med*. 2023;13(12):1654. doi: [10.3390/jpm13121654](https://doi.org/10.3390/jpm13121654)
 245. Liu YN, Qin Y, Wu B, et al. Dna methylation in polycystic ovary syndrome: emerging evidence and challenges. *Reprod Toxicol*. 2022;111:11–19. doi: [10.1016/j.reprotox.2022.04.010](https://doi.org/10.1016/j.reprotox.2022.04.010)
 246. Jia L, Zeng Y, Hu Y, et al. Homocysteine impairs porcine oocyte quality via deregulation of one-carbon metabolism and hypermethylation of mitochondrial DNAdagger. *Biol Reprod*. 2019;100(4):907–916.
 247. Laguna-Barraza R, Sanchez-Calabuig MJ, Gutierrez-Adan A, et al. Effects of the HDAC inhibitor scriptaid on the in vitro development of bovine embryos and on imprinting gene expression levels. *Theriogenology*. 2018;110:79–85. doi: [10.1016/j.theriogenology.2017.12.043](https://doi.org/10.1016/j.theriogenology.2017.12.043)
 248. Shao R, Suzuki T, Suyama M, et al. The impact of selective HDAC inhibitors on the transcriptome of early mouse embryos. *BMC Genomics*. 2024;25(1):143. doi: [10.1186/s12864-024-10029-3](https://doi.org/10.1186/s12864-024-10029-3)
 249. Li Q, Lu J, Yin X, et al. Base editing-mediated one-step inactivation of the DNMT gene family reveals critical roles of DNA methylation during mouse gastrulation. *Nat Commun*. 2023;14(1):2922. doi: [10.1038/s41467-023-38528-z](https://doi.org/10.1038/s41467-023-38528-z)
 250. Gu H, Gao J, Guo W, et al. The expression of DNA methyltransferases3A is specifically downregulated in chorionic villi of early embryo growth arrest cases. *Mol Medrep*. 2017;16(1):591–596. doi: [10.3892/mmr.2017.6650](https://doi.org/10.3892/mmr.2017.6650)
 251. Nowialis P, Lopusna K, Opavska J, et al. Catalytically inactive Dnmt3b rescues mouse embryonic development by accessory and repressive functions. *Nat Commun*. 2019;10(1):4374. doi: [10.1038/s41467-019-12355-7](https://doi.org/10.1038/s41467-019-12355-7)
 252. Tsume-Kajioka M, Kimura-Yoshida C, Mochida K, et al. Bet proteins are essential for the specification and maintenance of the epiblast lineage in mouse preimplantation embryos. *BMC Biol*. 2022;20(1):64. doi: [10.1186/s12915-022-01251-0](https://doi.org/10.1186/s12915-022-01251-0)
 253. Gacias M, Gerona-Navarro G, Plotnikov AN, et al. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression. *Chem Biol*. 2014;21(7):841–854. doi: [10.1016/j.chembiol.2014.05.009](https://doi.org/10.1016/j.chembiol.2014.05.009)
 254. Burmeister A, Stephan A, Alves Avelar LA, et al. Establishment and evaluation of dual HDAC/BET inhibitors as therapeutic options for

- germ cell tumors and other urological malignancies. *Mol Cancerther.* 2022;21(11):1674–1688. doi: [10.1158/1535-7163.MCT-22-0207](https://doi.org/10.1158/1535-7163.MCT-22-0207)
255. Megiorni F, Camero S, Pontecorvi P, et al. Otx015 epi-drug exerts antitumor effects in ovarian cancer cells by blocking GNL3-mediated radioresistance mechanisms: cellular, molecular and computational evidence. *Cancers (Basel).* 2021;13(7):1519. doi: [10.3390/cancers13071519](https://doi.org/10.3390/cancers13071519)
256. Blaschke K, Ebata KT, Karimi MM, et al. Vitamin C induces TET-dependent DNA demethylation and a blastocyst-like state in ES cells. *Nature.* 2013;500(7461):222–226. doi: [10.1038/nature12362](https://doi.org/10.1038/nature12362)
257. Oza AM, Matulonis UA, Alvarez Secord A, et al. A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer. *Clin Cancerres.* 2020;26(5):1009–1016. doi: [10.1158/1078-0432.CCR-19-1638](https://doi.org/10.1158/1078-0432.CCR-19-1638)
258. Klaver R, Sanchez V, Damm OS, et al. Direct but no transgenerational effects of decitabine and vorinostat on male fertility. *PLOS ONE.* 2015;10(2):e0117839. doi: [10.1371/journal.pone.0117839](https://doi.org/10.1371/journal.pone.0117839)
259. Shokry D, Khan MW, Powell C, et al. Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6B. *Cell Commun Signal.* 2024;22(1):528. doi: [10.1186/s12964-024-01912-3](https://doi.org/10.1186/s12964-024-01912-3)
260. Oing C, Verem I, Mansour WY, et al. 5-azacitidine exerts prolonged pro-apoptotic effects and overcomes cisplatin-resistance in non-seminomatous germ cell tumor cells. *Int J Mol Sci.* 2018;20(1):21. doi: [10.3390/ijms20010021](https://doi.org/10.3390/ijms20010021)
261. Wang L, Tan YJ, Wang M, et al. Dna methylation inhibitor 5-aza-2'-deoxycytidine modulates endometrial receptivity through upregulating HOXA10 expression. *Reprod Sci.* 2019;26(6):839–846. doi: [10.1177/1933719118815575](https://doi.org/10.1177/1933719118815575)
262. Gladkova MG, Leidmaa E, Anderzhanova EA. Epidrugs in the therapy of central nervous system disorders: a way to drive on? *Cells.* 2023;12(11):1464. doi: [10.3390/cells12111464](https://doi.org/10.3390/cells12111464)
263. Ghosh A, Himaja A, Biswas S, et al. Advances in the delivery and development of epigenetic therapeutics for the treatment of cancer. *Mol Pharm.* 2023;20(12):5981–6009. doi: [10.1021/acs.molpharmaceut.3c00610](https://doi.org/10.1021/acs.molpharmaceut.3c00610)
264. Ghorbaninejad M, Khademi-Shirvan M, Hosseini S, et al. Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation. *STEM Cell resther.* 2020;11(1):456. doi: [10.1186/s13287-020-01966-3](https://doi.org/10.1186/s13287-020-01966-3)
265. Li Y. Modern epigenetics methods in biological research. *Methods.* 2021;187:104–113. doi: [10.1016/j.jymeth.2020.06.022](https://doi.org/10.1016/j.jymeth.2020.06.022)
266. Franzago M, La Rovere M, Guanciali Franchi P, et al. Epigenetics and human reproduction: the primary prevention of the noncommunicable diseases. *Epigenomics.* 2019;11(12):1441–1460. doi: [10.2217/epi-2019-0163](https://doi.org/10.2217/epi-2019-0163)
267. Novakovic B, Lewis S, Halliday J, et al. Assisted reproductive technologies are associated with limited epigenetic variation at birth that largely resolves by adulthood. *Nat Commun.* 2019;10(1):3922. doi: [10.1038/s41467-019-11929-9](https://doi.org/10.1038/s41467-019-11929-9)
268. Kagami M, Hara-Isono K, Sasaki A, et al. Association between imprinting disorders and assisted reproductive technologies. *Epigenomics.* 2025;17(6):397–410. doi: [10.1080/17501911.2025.2471269](https://doi.org/10.1080/17501911.2025.2471269)
269. Ganesan A, Arimondo PB, Rots MG, et al. The timeline of epigenetic drug discovery: from reality to dreams. *Clin Epigenet.* 2019;11(1):174. doi: [10.1186/s13148-019-0776-0](https://doi.org/10.1186/s13148-019-0776-0)
270. Gemmati D, Villanova M, Scarpellini F, et al. Epigenetic modifications and transgenerational inheritance in women victims of violence EWWV. *Environ Epigenet.* 2025;dvaf025. doi: [10.1093/eeep/dvaf025](https://doi.org/10.1093/eeep/dvaf025)
271. Gemmati D, Tisato V. Chapter 24 - Genomic and epigenomic signature at the branch-point among genome, phenome, and sexome in health and disease: a multiomics approach. In: *Principles of gender-specific medicine.* 2023. p. 393–408. doi: [10.1016/B978-0-323-88534-8.00019-5](https://doi.org/10.1016/B978-0-323-88534-8.00019-5)
272. Miranda Furtado CL, Dos Santos Luciano MC, Silva Santos RD, et al. Epidrugs: targeting epigenetic marks in cancer treatment. *Epigenetics.* 2019;14(12):1164–1176.